Latest news for Helix BioPharma (OTC:HBPCF) Stock

Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidates are Tumor Defence Breaker L-DOS47, and, V-DOS47 among others.

Penny Stocks

HBPCF

TSX:HBP


  By John Vandermosten, CFA

TSX:HBP.TO | OTC:HBPCF

HBP.TO: Third Quarter Fiscal Year 2021 Operational and Financial Results


  By John Vandermosten, CFA

TSX:HBP.TO | OTC:HBPCF 

HBP.TO: Private Placement Completed

HBP.TO: Pancreatic Trial Enrolling

HELIX BIOPHARMA CORP by Helix Biopharma Corp.

Helix BioPharma Corp

Needham analyst Laura Martin reiterates DoubleVerify Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DV#NYSE">DV</a>) with a Buy and maintains $33 price target.

News

Price Target

Reiteration

Analyst Ratings

Needham Reiterates Buy on DoubleVerify Hldgs, Maintains $33 Price Target

Shares of SAP SE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAP#NYSE">SAP</a>) rose sharply in today's pre-market trading after the company reported <a href="https://www.benzinga.com/news/earnings/24/07/39895236/sap-stock-is-up-after-q2-results-heres-a-look-at-the-details">second-quarter financial results.</a>
SAP reported quarterly earnings of 82 cents per share which missed the analyst consensus estimate of $1.19 per share. Quarterly sales came in at $8.92 billion which missed the analyst consensus estimate of $8.96 billion, representing an 8.81% increase over sales from the same period last year, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
SAP shares gained 5.9% to $212.34 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Nature&#8217;s Miracle Holding Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMHI#NASDAQ">NMHI</a>) rose 183.4% to $0.9779 in pre-market trading after falling 13% on Monday.</li>
<li>Volato Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOAR#NYSE">SOAR</a>) gained 140.5% to $1.15 in pre-market trading after jumping around 20% on Monday.</li>
<li>Frequency Electronics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEIM#NASDAQ">FEIM</a>) shares climbed 32% to $13.33 in pre-market trading following fourth-quarter earnings. Also, the company declared a $1.00 special cash dividend.</li>
<li>MSP Recovery, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIFW#NASDAQ">LIFW</a>) gained 24.6% to $0.6319 in pre-market trading after the company announced a settlement with another group of affiliated P&amp;C insurers.</li>
<li>Mammoth Energy Services, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TUSK#NASDAQ">TUSK</a>) shares gained 23.1% to $4.31 in pre-market trading after the company announced its subsidiary, Cobra Acquisitions, entered into a release and settlement agreement with the Puerto Rico Electric Power Authority.</li>
<li>MAIA Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAIA#NASDAQ">MAIA</a>) gained 22.9% to $4.61 in pre-market trading after reporting Phase 2 results for lung cancer treatment THIO.</li>
<li>Professional Diversity Network, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPDN#NASDAQ">IPDN</a>) shares gained 20.2% to $0.59 in pre-market trading.</li>
<li>New Horizon Aircraft Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOVR#NASDAQ">HOVR</a>) shares gained 13.5% to $0.6105 in pre-market trading after falling over 8% on Monday.</li>
<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) shares surged 12.5% to $8.50 in pre-market trading. Mesoblast recently started enrollment in Phase 3 trial of Rexlemestrocel-L for chronic low back pain.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>TransCode Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) shares fell 57.2% to $0.3395 in pre-market trading. TransCode Therapeutics priced its $3 million public offering of 10 million common shares at $0.30 per share.</li>
<li>MIRA Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NASDAQ">MIRA</a>) shares fell 30.3% to $3.49 in pre-market trading. MIRA Pharmaceuticals shares jumped 627% on Monday after the company announced new preclinical study results for its novel oral ketamine analog, Ketamir-2.</li>
<li>CareMax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMAX#NASDAQ">CMAX</a>) shares fell 25.3% to $3.87 in pre-market trading after surging 228% on Monday.</li>
<li>Nukkleus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUKK#NASDAQ">NUKK</a>) shares declined 21.5% to $0.3910 in pre-market trading after gaining over 55% on Monday.</li>
<li>Exicure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) shares fell 17.5% to $0.41 in pre-market trading after declining around 7% on Monday.</li>
<li>Castellum, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTM#NYSE">CTM</a>) fell 15% to $0.17 in pre-market trading. Castellum recently announced a new strategic alliance with Krilla Kaleiwahea.</li>
<li>Medpace Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) shares declined 12.6% to $382.00 in pre-market trading after the company reported mixed second-quarter financial results and narrowed its FY24 revenue guidance with its midpoint below estimates.</li>
<li>Netcapital Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCPL#NASDAQ">NCPL</a>) fell 11.8% to $0.0989 in pre-market trading after gaining around 8% on Monday.</li>
<li>Stem, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) shares dipped 11.4% to $1.17 in pre-market trading after gaining 7% on Monday.</li>
<li>NXP Semiconductors N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) shares fell 9.1% to $258.03 in pre-market trading following mixed second-quarter earnings.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39881526/wall-streets-most-accurate-analysts-say-hold-these-3-utilities-stocks-with-over-5-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Say Hold These 3 Utilities Stocks With Over 5% Dividend Yields</a></li>
</ul>

Pre-Market Outlook

Markets

Movers

Trading Ideas

CMAX

FEIM

HOVR

IPDN

LIFW

MAIA

MEDP

MESO

MIRA

NCPL

NMHI

NUKK

NXPI

RNAZ

SOAR

STEM

TUSK

XCUR

Why SAP Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

Robert Kiyosaki, the author of the best-selling book &#8220;Rich Dad Poor Dad,&#8221; has predicted a significant surge in the prices of Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), gold, and silver if former President Donald Trump wins <a href="https://www.benzinga.com/topic/2024-election">the 2024 election</a>.
What Happened: Kiyosaki took to X to share his forecast. He suggested that a Trump presidency would lead to a weaker dollar, boosting exports and job creation, and consequently driving up the prices of assets like Bitcoin, gold, and silver. Kiyosaki also predicted a decrease in oil prices if Trump is re-elected, further contributing to the rise in asset prices.
Kiyosaki compared Trump&#8217;s policies to those of President Joe Biden, stating that Biden&#8217;s actions led to a significant increase in oil prices, causing inflation that adversely affected the poor and middle class.
Kiyosaki wrote that Trump will &#8220;Make America Great Again.&#8221; The author predicted that the former president <a href="https://www.benzinga.com/news/24/07/39853222/trump-blasts-crazy-nancy-pelosi-vows-to-end-inflation-and-claims-kim-jong-un-misses-him-in-rnc-addre">would adopt the slogan</a> &#8220;Drill, baby, drill,&#8221; a line echoed during Trump's speech at the Republican National Convention.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Why GOLD, SILVER, BITCOIN will rise in price when TRUMP becomes President again. Trump wants a weaker dollar so America will begin export more than import. With a weaker dollar jobs will come back and assets will go up in price. Trump is going to drill, drill, drill for oil…
&mdash; Robert Kiyosaki (@theRealKiyosaki) <a href="https://twitter.com/theRealKiyosaki/status/1815607168940617813?ref_src=twsrc%5Etfw">July 23, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39872368/mark-cuban-says-trumps-re-election-wont-impact-bitcoins-price-dogecoin-killer-shiba-inus-b?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Mark Cuban Says Trump&#8217;s Re-Election Won&#8217;t Impact Bitcoin&#8217;s Price, &#8216;Dogecoin Killer&#8217; Shiba Inu&#8217;s Burn Rate Increases And More: This Week In Cryptocurrency</a>
He concluded his post by predicting that the price of gold would rise from $2,400 an ounce to $3,300, silver from $29.00 an ounce to $79.00, and Bitcoin from $67,400 per coin to $105,000 by August 2025 if Trump is re-elected.
Why It Matters: Kiyosaki&#8217;s predictions are rooted in his <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39722140/rich-dad-poor-dad-author-robert-kiyosaki-bats-for-bitcoin-even-as-his-350k-prediction-for-">long-standing advocacy for Bitcoin</a> and precious metals. Recently, he urged investors to buy more Bitcoin and precious metals to &#8220;turn a bad hand into a great hand.&#8221; He warned that millions could lose out if they don&#8217;t heed his advice.
The potential impact of Trump&#8217;s policies on <a href="https://www.benzinga.com/news/24/07/39810934/trumps-second-term-could-trigger-global-inflation-warn-analysts-2024-2025-is-going-to-be-very-differ">global markets is significant</a>. Analysts have warned that a second term for Trump could trigger global inflation, driven by his &#8220;America-first&#8221; policies. These policies, characterized by high tariffs and low taxes, could have a more pronounced inflationary effect if repeated.
Moreover, Trump&#8217;s comments on Taiwan and Biden&#8217;s trade restriction plans have already <a href="https://www.benzinga.com/markets/equities/24/07/39829923/trumps-taiwan-talk-bidens-trade-restriction-plans-trigger-nvidia-amd-and-other-semiconductor-sel">caused a selloff in semiconductor</a> stocks, highlighting the market&#8217;s sensitivity to geopolitical developments.
It&#8217;s worth noting that Kiyosaki and Trump have a <a href="https://www.benzinga.com/real-estate/24/01/36597818/donald-trump-and-rich-dad-poor-dad-author-robert-kiyosaki-teamed-up-to-write-a-book-and-make-financi">history of collaboration</a>, having co-authored a book and produced financial education videos together. Their shared views on real estate and economic policies have been well-documented.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/24/07/39877083/elon-musk-may-have-endorsed-trump-but-tesla-would-have-done-even-worse-without-bidens-7-5k-ev-tax-cr?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk May Have Endorsed Trump, But Tesla Would Have Done &#8216;Even Worse&#8217; Without Biden&#8217;s $7.5K EV Tax Credit, Says Fund Manager</a></li>
</ul>
Image created using photos on Flickr and Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Kaustubh-Bagalkote" target="_blank" rel="noreferrer noopener">Kaustubh Bagalkote</a>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Politics

Economics

$BTC

'Rich Dad Poor Dad' Author Robert Kiyosaki Predicts Bitcoin, Gold, And Silver Prices Will Soar If Trump Wins 2024 Election, Says King Crypto Will Reach $105K

Baird analyst Rob Oliver initiates coverage on Monday.Com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) with a Neutral rating and announces Price Target of $250.

Initiation

MNDY

Baird Initiates Coverage On Monday.Com with Neutral Rating, Announces Price Target of $250

In a significant strategic move, Toyota Motor Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TM#NYSE">TM</a>) has announced plans to repurchase ¥806.8 billion ($5.2 billion) of its shares from key Japanese banks and insurers. The move is part of a broader strategy to untangle its shareholdings with financial partners.
What Happened: The shares will be bought back from Mitsubishi UFJ Financial Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUFG#NYSE">MUFG</a>), Sumitomo Mitsui Financial Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMFG#NYSE">SMFG</a>), Tokio Marine Holdings Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TKOMY#OTC">TKOMY</a>), and MS&amp;AD Insurance Group Holdings Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MSADY#OTC">MSADY</a>) at ¥2,781 each, an 11% discount to their closing price on Tuesday, Bloomberg <a href="https://www.benzinga.com/markets/equities/24/06/39228602/japanese-mega-banks-plan-8-5b-toyota-stake-sale-report">reported</a> on Tuesday.
This move is part of a ¥1 trillion ($6.4 billion) repurchase plan announced by Toyota in May, aimed at satisfying the Japanese government&#8217;s push for large corporations to unwind cross-held shareholdings. The deal could potentially trigger a broader wave of looser equity ties in Japan.
Why It Matters: This strategic move is a response to the<a href="https://www.benzinga.com/markets/equities/24/06/39228602/japanese-mega-banks-plan-8-5b-toyota-stake-sale-report"> Japanese government&#8217;s push</a> for corporations to dismantle their extensive network of cross-held shares. Toyota&#8217;s share buyback initiative, announced in May, is a significant increase from previous repurchases.
Toyota&#8217;s shares have climbed 26% this year, following a 43% rally in 2023. The banks and insurers plan to divest their Toyota shareholdings over a few years, significantly reducing their stakes or divesting them entirely.
See Also: <a href="https://www.benzinga.com/markets/equities/24/07/39871513/trump-pours-cold-water-on-industry-tesla-falls-ahead-of-earnings-week-fords-step-back-in-ev-plan?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump Pours Cold Water On Industry, Tesla Falls Ahead Of Earnings Week, Ford&#8217;s Step-back In EV Plans And More: Biggest EV Stories Of The Week</a>
Recently, Toyota has announced that its internal investigation into car model certification applications has not uncovered any further <a href="https://www.benzinga.com/news/24/07/39640788/toyota-says-it-has-not-found-any-further-wrongdoing-in-certification-applications-beyond-those-repor">instances of misconduct</a>, beyond those previously reported. This investigation was initiated in response to an industry-wide directive from the Japanese transport ministry, following a safety test scandal at Toyota's Daihatsu compact car unit.
Furthermore, Toyota&#8217;s electric vehicle (EV) sales <a href="https://www.benzinga.com/markets/penny-stocks/24/07/39671005/toyota-has-finally-hit-the-accelerator-on-its-ev-journey">quadrupled in the second quarter,</a> with the company selling almost 250,000 hybrid and electric models. This represents a year-over-year rise of 63%, representing almost 40% of the group&#8217;s total volume. EVs and PHEVs are undoubtedly Toyota's fastest-growing segment.
Price Action: Toyota Motor stock closed at $200.14 on Monday, according to<a href="https://pro.benzinga.com"> Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39878361/tesla-ceo-elon-musk-clarifies-he-has-literally-zero-business-interests-in-russia-slams-podcast-host?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Tesla CEO Elon Musk Clarifies He Has &#8216;Literally Zero&#8217; Business Interests In Russia, Slams Podcast Host Sam Harris: &#8216;Pompous Hypocrite…&#8217;</a></li>
</ul>
Photo by josefkubes on Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Asia

Buybacks

Global

General

MSADY

MUFG

SMFG

TKOMY

Toyota Announces $5.2B Share Buyback From Japanese Banks And Insurers

Baird analyst Matthew Krueger initiates coverage on AZZ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZZ#NYSE">AZZ</a>) with a Neutral rating and announces Price Target of $90.

Baird Initiates Coverage On AZZ with Neutral Rating, Announces Price Target of $90

Baird analyst Rob Oliver initiates coverage on Vertex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERX#NASDAQ">VERX</a>) with a Outperform rating and announces Price Target of $43.

VERX

Baird Initiates Coverage On Vertex with Outperform Rating, Announces Price Target of $43

EV giant Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has started rolling out <a href="https://www.benzinga.com/news/24/07/39855931/elon-musk-says-tesla-will-deploy-fsd-in-cybertrucks-with-version-12-5-stays-mum-on-fresh-timeline-af">version 12.5 of its full self-driving (FSD)</a> driver assistance software to select drivers but it doesn&#8217;t allow drivers to wear sunglasses still.
What Happened: While the newly rolled-out version is yet to allow users to wear sunglasses or enable complete hands-off driving on highways, those features will be deployed in future versions of the software, a senior Tesla executive confirmed on X. 
&#8220;End-to-end on the highway is coming in follow-up 12.5.x releases. So is driver monitoring support for sun glasses,&#8221; Ashok Elluswamy wrote. Elluswamy is Tesla's Director of Autopilot software. 
FSD currently does not work well with sunglasses as its attention monitoring system tracks eye movements to ensure users are paying attention to the road and are ready to take over as required.
However, the issue should be solved with version 12.5 of the software, <a href="https://www.benzinga.com/news/24/07/39877043/tesla-fsd-to-allow-users-to-wear-sunglasses-starting-with-version-12-5-elon-musk-tells-quake-video-g">Musk told video game developer</a> John Carmack on Saturday.
Tesla did not immediately respond to <a href="https://pro.benzinga.com/dashboard">Benzinga&#8217;s</a> request for comment.
Why It Matters:&nbsp;Tesla is attempting to improve its FSD software to enable vehicles to operate without human intervention. However, it presently requires active driver supervision.
In May, Musk said that&nbsp;<a href="https://www.benzinga.com/news/24/07/39855931/elon-musk-says-tesla-will-deploy-fsd-in-cybertrucks-with-version-12-5-stays-mum-on-fresh-timeline-af" target="_blank" rel="noreferrer noopener">version 12.5 of FSD</a> will start rolling out in late June. However, there seems to have been a delay with the software rolling out to select Tesla drivers only on Monday. 
While many Tesla customers are on version 12.4 of the software, some are on further older versions.
Musk has previously also said that the company will start deploying FSD on its&nbsp;<a href="https://www.benzinga.com/news/24/07/39808526/cybertruck-curiosity-grips-tesla-shareholders-as-elon-musk-led-ev-giant-starts-taking-questions-for" target="_blank" rel="noreferrer noopener">Cybertruck vehicles&nbsp;</a>with version 12.5. It is unclear if any Cybertruck drivers have gotten access as of today. 
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link</a>.
Read More:
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39899497/spacex-bags-113m-nasa-contract-to-launch-satellite-system-for-monitoring-earths-environment">SpaceX Bags $113M NASA Contract To Launch Satellite System For Monitoring Earth&#8217;s Environment</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

TSLA

Tesla's FSD Version 12.5 Doesn't Support Sunglasses Yet, Contrary To Elon Musk's Word

Piper Sandler analyst Arvind Ramnani maintains Globant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLOB#NYSE">GLOB</a>) with a Overweight and maintains $238 price target.

GLOB

Piper Sandler Maintains Overweight on Globant, Maintains $238 Price Target

In a recent development, Warner Bros Discovery&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>) sports network, TNT Sports, has declared its intention to match one of the three bids for the broadcast rights of National Basketball Association games. 
What Happened: The decision is aimed at maintaining TNT Sports&#8217; long-standing four-decade relationship with the NBA. While the network has not disclosed which NBA programming package it plans to match, a source close to the matter has revealed that TNT Sports is considering matching Amazon Prime Video&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) $1.9 billion per season bid for an 11-year contract, Reuters reported on Tuesday. 
Upon being informed about the finalized deals by the league, Warner&#8217;s sports unit was given a five-day window to decide whether to match one of the bids. 
See Also: <a href="https://www.benzinga.com/markets/24/07/39877083/elon-musk-may-have-endorsed-trump-but-tesla-would-have-done-even-worse-without-bidens-7-5k-ev-tax-cr?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk May Have Endorsed Trump, But Tesla Would Have Done &#8216;Even Worse&#8217; Without Biden&#8217;s $7.5K EV Tax Credit, Says Fund Manager</a>
&#8220;We have reviewed the offers and matched one of them,&#8221; TNT stated. 
&#8220;This will allow fans to keep enjoying our unparalleled coverage.&#8221;
Why It Matters: This move comes on the heels of the <a href="https://www.benzinga.com/general/entertainment/24/07/39733479/nba-fans-rejoice-new-76b-deal-from-espn-amazon-nbc-will-bring-games-seven-days-a-week">NBA finalizing agreements</a> with Walt Disney&#8217;s (DIS.N) ESPN, Comcast&#8217;s (CMCSA.O) NBCUniversal, and Amazon. These deals, collectively valued at $76 billion, are set to commence post the 2024-25 season. 
However, this decision might lead to legal complications if the <a href="https://www.benzinga.com/news/24/05/38768312/warner-bros-discovery-eyes-turnaround-with-upcoming-disney-bundle-and-nba-deal-analysts-say">NBA rejects the matching bid</a>. It could also potentially harm WBD&#8217;s standing among other sports leagues, as per Emarketer senior analyst Ross Benes. This comes at a time when Warner Bros. Discovery is eyeing a turnaround with its upcoming Disney+ Bundle and NBA deal.
Price Action: During Tuesday&#8217;s pre-market, Warner Bros. Discovery was trading 1.38% lower than its Monday close of $8.480 while Amazon was trading 0.32% lower than its previous close of $182.90, according to <a href="https://pro.benzinga.com">Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39877645/mohamed-el-erian-on-bidens-withdrawal-from-presidential-race-there-is-genuine-uncer?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Mohamed El-Erian On Biden&#8217;s Withdrawal From Presidential Race: &#8216;There Is Genuine Uncertainty On How Markets Will &#8211; And Should- React To The News&#8217;</a></li>
</ul>
NBA by Shaheerrr via Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Sports

AMZN

Warner Bros Discovery's TNT Sports Counters Amazon With $1.9B NBA Broadcast Rights Bid: Report

Piper Sandler analyst Brent Bracelin reiterates Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) with a Overweight and raises the price target from $465 to $485.

MSFT

Piper Sandler Reiterates Overweight on Microsoft, Raises Price Target to $485

Tesla Inc. CEO Elon Musk refuted claims of <a href="https://www.benzinga.com/news/24/07/39784950/elon-musk-to-pour-45m-monthly-in-pro-trump-super-pac-joined-by-palantirs-joe-lonsdale-winklevoss-twi">donating $45 million monthly</a> to former President Donald Trump&#8216;s campaign. The billionaire revealed the true purpose of his political action committee (PAC.)
What Happened: In an interview with psychologist and conservative commentator Dr. Jordan Peterson, Musk clarified that the media&#8217;s reports were inaccurate. He stated that he was not donating $45 million monthly to Trump. Instead, he has established a PAC, &#8220;The America PAC.&#8221;
Musk explained that a PAC is a legal entity that can receive funding and use it to support political campaigns. This differs from direct donations to candidates, which have specific limits. The PAC system allows for more money to flow into the political system than would otherwise be possible.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">My conversation with <a href="https://twitter.com/elonmusk?ref_src=twsrc%5Etfw">@elonmusk</a>. Live today at 3pm ET. <a href="https://t.co/RyaZFmvC8i">https://t.co/RyaZFmvC8i</a>
&mdash; Dr Jordan B Peterson (@jordanbpeterson) <a href="https://twitter.com/jordanbpeterson/status/1815427698703090085?ref_src=twsrc%5Etfw">July 22, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
He added that these PACs and Super PACs are used on both the Democratic and Republican sides, creating an open playing field.
&#8220;The intent is to promote the principles that made America great in the first place, so I wouldn&#8217;t say that I&#8217;m, say, for example, &#8216;MAGA&#8217; of &#8216;Make America Great Again.&#8217; I think America is great; I&#8217;m more &#8216;MAG&#8217;—Make America Greater,&#8221; Musk said.
See Also: <a href="https://www.benzinga.com/news/24/07/39880470/elon-musk-pushes-back-optimus-timeline-says-teslas-humanoid-robot-will-hopefully-be-available-for-ot?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Pushes Back Optimus Timeline, Says Tesla&#8217;s Humanoid Robot Will &#8216;Hopefully&#8217; Be Available For Other Companies By 2026</a>
Key principles include promoting a meritocracy, where success is based on hard work and skill, rather than nepotism or dynasties, according to Musk. Another principle is promoting freedom and minimizing government intervention.
Why It Matters: The controversy began when <a href="https://www.benzinga.com/news/24/07/39784950/elon-musk-to-pour-45m-monthly-in-pro-trump-super-pac-joined-by-palantirs-joe-lonsdale-winklevoss-twi">reports surfaced last week</a> claiming that Musk was committing $45 million monthly to a pro-Trump Super PAC. This report was met with skepticism and led Musk to respond with a &#8220;Fake Gnus&#8221; post on social media, indicating his disapproval of the misinformation.
Adding to the complexity, Musk had previously revealed that <a href="https://www.benzinga.com/news/24/06/39325921/elon-musk-reveals-donald-trumps-surprising-stance-on-evs-says-former-president-is-huge-fan-of-the-te">Trump was a fan</a> of Tesla&#8217;s Cybertruck, despite his public criticism of the electric vehicle industry. This revelation came during Tesla's annual meeting, where Musk mentioned that Trump frequently called him, though the reasons for these calls were unclear.
The situation took another turn when it was reported that Musk had pledged a significant <a href="https://www.benzinga.com/news/24/07/39872015/teslas-elon-musk-recently-pledged-a-huge-donation-to-donald-trump-and-the-ex-president-returned-the">$180 million donation</a> to Trump's campaign. However, Trump's speech at the Republican National Convention criticized the EV industry, leading to accusations of betrayal.
Further complicating matters, Gov.&nbsp;Gavin Newsom&nbsp;(D-Calif.) took a jab at Musk referencing a 2022 post by Trump that suggested Musk had sought his <a href="https://www.benzinga.com/markets/equities/24/07/39815808/elon-musk-claps-back-after-gavin-newsom-shares-donald-trumps-drop-to-your-knees-and-beg-post-abo">assistance for subsidized projects</a>. Newsom's post came after Musk relocated the headquarters of two of his companies from California to Texas.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39846836/california-ev-subsidies-made-tesla-what-it-is-but-elon-musk-is-ready-to-cut-them-off-remove-subsidie?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">California EV Subsidies Made Tesla What It Is, But Elon Musk Is Ready To Cut Them Off: &#8216;Remove Subsidies From All Industries&#8217;</a></li>
</ul>
Image Via Flickr 
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Kaustubh-Bagalkote" target="_blank" rel="noreferrer noopener">Kaustubh Bagalkote</a>

Elon Musk Denies $45M Monthly Donation To Trump, Clarifies True Purpose Of 'The America PAC' In Interview With Jordan Peterson

<a href="https://www.bloomberg.com/news/articles/2024-07-23/apple-and-micron-leaders-visit-china-as-us-ramps-up-chip-curbs" title="https://www.bloomberg.com/news/articles/2024-07-23/apple-and-micron-leaders-visit-china-as-us-ramps-up-chip-curbs">https://www.bloomberg.com/news/articles/2024-07-23/apple-and-micron-leaders-visit-china-as-us-ramps-up-chip-curbs</a>

AAPL

Bloomberg Reported Apple COO Jeff Williams And Micron President Sanjay Mehrotra Visit Beijing Amid US Tech Curbs

Popular workplace messaging app Slack, owned by Salesforce Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) has introduced a new set of widgets for its iPhone app.
What Happened: The new widgets, three for the iPhone&#8217;s home screen and one for the lock screen, are designed to improve the accessibility of the Slack app. The lock screen widget enables users to access the Slack app directly after unlocking their devices.
The home screen widgets include &#8220;Catch Up,&#8221; which offers a quick summary of unread messages and mentions without the need to open the app. It directs users straight&nbsp;to that section of the&nbsp;Slack app, allowing them to quickly navigate through missed conversations.
See Also:&nbsp;<a href="https://www.benzinga.com/news/24/07/39872729/nvidias-potential-50-trillion-valuation-tesla-and-xais-ai-expansion-plans-and-microsofts-trillion-do?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Nvidia&#8217;s Potential $50 Trillion Valuation, Tesla And xAI&#8217;s AI Expansion Plans, And Microsoft&#8217;s Trillion-Dollar Tech: This Week In Artificial Intelligence</a>
The other two homescreen widgets&nbsp;streamline Slack status updates. The smaller &#8220;Status&#8221; widget guides users&nbsp;to that section of the&nbsp;Slack iOS app, while a&nbsp;larger version provides the same functionality with three preset status options: one-hour &#8220;Focus&#8221; and &#8220;Lunch&#8221; statuses, and a half-hour &#8220;Take a break&#8221; status. 
However, these preset options are not customizable right now.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Three &#x33;&#x20e3;new Slack iOS widgets are here to make your workday a whole lot easier. &#x1f44f; Add the Catch Up widget, Status widget, and Slack Launcher widget to your device and stay in the know on the go. <a href="https://t.co/bEak0coGZK">pic.twitter.com/bEak0coGZK</a>
&mdash; Slack (@SlackHQ) <a href="https://twitter.com/SlackHQ/status/1815379785058533774?ref_src=twsrc%5Etfw">July 22, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters: Earlier this year, it was reported that some companies use artificial intelligence to <a href="https://www.benzinga.com/news/24/02/37053808/from-slack-to-surveillance-heres-how-companies-monitor-your-communications-with-ai">monitor employee communications on platforms</a> like Slack. The idea behind this is to have a digital eye on employee interactions.
In May, Salesforce, the parent company of Slack, reported its <a href="https://www.benzinga.com/news/earnings/24/05/39073628/salesforce-stock-dives-on-q1-earnings-revenue-miss-eps-beat-weak-guidance-and-more">reported first-quarter revenue</a> of $9.13 billion, falling short of the consensus estimate of $9.147 billion. This represented an 11% increase compared to the same period last year, according to&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Check out more of Benzinga's Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:&nbsp;<a href="https://www.benzinga.com/news/24/07/39830453/days-after-elon-musk-deemed-university-of-tokyos-idea-pointless-scientists-develop-smiling-robot-wit?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Days After Elon Musk Deemed University Of Tokyo&#8217;s Idea &#8216;Pointless,&#8217; Scientists Develop Smiling Robot With Living Skin</a>
Disclaimer:&nbsp;This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Photo courtesy: Unsplash

Slack Introduces New iPhone Widgets To Improve Accessibility And Make Workday Easier

An unconditional monthly $1,000 cash payment to low-income groups increased their ability to meet basic needs and support others, according to the final results from the Universal Basic Income study sponsored by the<a href="https://www.benzinga.com/markets/equities/24/07/39856365/openai-in-talks-with-broadcom-to-develop-new-ai-chip-aims-to-reduce-reliance-on-nvidia-report"> Sam Altman-led OpenAI project</a>, OpenResearch, published on Sunday.
The three-year study delved into the impact on a series of employment outcomes in a group of 1,000 low-income individuals, who were paid $1,000 per month unconditionally. A control group of 2,000 participants received $50 per month. The experiment was carried out in the states of Texas and Illinois.
Impact On Employment: By the end of the three-year period, it was <a href="https://www.openresearchlab.org/findings">found </a>that employment rates rose from 58% at the start to 72% among recipients. The transfer, however, caused total individual income to fall by about $1,500 per year relative to the control group, excluding the transfers. 
The labor market participation fell by 2% points for participants and labor hours were reduced by 1.3-1.4 hours per week. Participants' partners reduced their hours worked by a comparable amount.
The study found that the transfer led to the largest increase in time spent on leisure but smaller increases in time spent on other activities such as transportation and finances. &#8220;Overall, our results suggest a moderate labor supply effect that does not appear offset by other productive activities,&#8221; study authors, who include OpenResearch personnel, and academicians, said.
&#8220;Cash can increase people's agency to make employment decisions that align with their individual circumstances, goals, and values. Recipients were more likely to be searching for a job, but they were more selective,&#8221; they said.&#8217;
A testimonial statement by a study participant named Jessie said, &#8220;Because of the [cash transfer] and being able to build up my savings, I&#8217;m in a position for once to be picky…I don&#8217;t have to take a crappy job just because I need income right now. I have the opportunity to hold out and try and find the right fit.&#8221;
See Also: <a href="https://www.benzinga.com/money/best-artificial-intelligence-stocks">Best Artificial Intelligence Stocks</a>
Health: The study found that unconditional cash transfers increased recipients&#8217; use of hospital and emergency department care and some types of office-based medical care, particularly dental and specialist care. Notable improvements were observed in stress, mental distress, and food security in the first year of the year study but the positive impact faded out during the later years of the study. 
Study participants reported decreased problematic alcohol use and some types of illicit drug abuse. &#8220;Although we find no significant effects on measures of physical health, self-reported access to health care, or on health-promoting behaviors such as exercise or sleep, the increased utilization of medical care may lead to long-term health benefits,&#8221; the researchers said.
Spending: Recipients were found increasing their spending by $310 per month. On average, recipients increased their monthly spending on food by $67, rent by $52 and transportation by $50. Cash provided the flexibility to meet diverse needs, and to support others.
Why It&#8217;s Important: Altman pledged financial support to the project in 2016 just after OpenAI was set up. The OpenAI co-founder, who was running Y Combinator, explained the logic of the study in a blog on the startup incubator&#8217;s website at that time. 
&#8220;I'm fairly confident that at some point in the future, as <a href="https://www.benzinga.com/general/24/05/39044740/probably-none-of-us-will-have-a-job-elon-musk-predicts-massive-job-losses-due-to-ai">technology continues to eliminate traditional jobs and massive new wealth gets created</a>, we're going to see some version of this at a national scale,&#8221; he said. The entrepreneur said the study would answer several questions, including &#8220;Do people sit around and play video games, or do they create new things? Are people happy and fulfilled? Do people, without the fear of not being able to eat, accomplish far more and benefit society far more? And do recipients, on the whole, create more economic value than they receive?&#8221;
Other tech leaders such as Tesla&#8217;s Elon Musk, Block Inc.&#8217;s Jack Dorsey and Salesforce&#8217;s Marc Benioff, have also backed &#8220;cash payments with no strings attached as a potential antidote to the negative effects of technology automating people's occupations,&#8221; Bloomberg <a href="https://www.bloomberg.com/news/articles/2024-07-22/ubi-study-backed-by-openai-s-sam-altman-bolsters-support-for-basic-income">said</a> in a report. The report also noted a sharp increase in local basic-income pilots in 2020 that aimed to &#8220;use cash as a tool for economic and racial justice, and test its potential to bolster the social safety net.&#8221;
However, detractors and opponents fear that recipients will take the money and drop out of the labor force or use the money on vices. it added.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/05/27339602/cathie-wood-has-cure-for-sagging-gdp-growth-sees-this-technology-accelerating-annua">Cathie Wood Sees This Technology Accelerating GDP Growth To 50% Per Year</a></li>
</ul>
Photo via Shutterstock

Government

Education

Health Care

Sam Altman Stands Vindicated? OpenAI-Sponsored 'No-Strings Payment' Study Quells Fears About Misuse Of Money, Making Strong Case For Universal Basic Income When AI Makes Jobs Obsolete

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk has once again stirred controversy <a href="https://www.benzinga.com/news/24/07/39876926/elon-musk-says-its-high-time-for-an-ai-fashion-show-shares-video-of-mark-zuckerberg-in-a-reptile-sui">with his social media activity</a>, and this time it could have implications for his company&#8217;s business in China.
What Happened: On Monday, Musk posted a video on X that featured a parody of an AI fashion show. The video included Musk, Bill Gates, and other prominent figures, as well as a brief appearance by Chinese leader Xi Jinping.
In the video, Xi is seen wearing a robe with a cartoon bear that resembles Winnie the Pooh, a character that has been used to mock the Chinese leader for over a decade. In 2013, Xi was the subject of memes comparing him to Pooh after a photo surfaced of him walking next to then-President Barack Obama, whom people likened to Tigger.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">High time for an AI fashion show <a href="https://t.co/ra6cHQ4AAu">pic.twitter.com/ra6cHQ4AAu</a>
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1815187468691316946?ref_src=twsrc%5Etfw">July 22, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The use of this character is a sensitive issue in China and has previously led to international incidents, such as the blocking of HBO after an episode of John Oliver&#8216;s show made fun of Xi&#8217;s alleged sensitivity to the character, <a href="https://www.businessinsider.com/elon-musk-xi-jinping-red-line-winnie-pooh-video-tweet-2024-7?_gl=1&#x2A;1topllz&#x2A;_ga&#x2A;NTg5OTA1MDc2LjE3MTI4ODMyNTA.&#x2A;_ga_E21CV80ZCZ&#x2A;MTcyMTcxMTc5OC4yMDEuMS4xNzIxNzExODA1LjUzLjAuM">reported</a> Business Insider.
China is a crucial market for Musk&#8217;s company, accounting for 22% of its total revenue in 2023. Musk has been actively expanding Tesla&#8217;s operations in China, including a deal to roll out autonomous driving software in the country.
However, Musk, who is outspoken on <a href="https://www.benzinga.com/news/24/04/38135953/elon-musk-hit-with-obstruction-of-justice-inquiry-after-he-calls-for-impeachment-of-brazils-top-judg">free speech issues</a>, often takes public risks. For example, he swore at advertisers during a conference, accusing them of <a href="https://www.benzinga.com/news/24/01/36483004/elon-musk-wages-war-gets-no-push-back-iger-cant-be-throwing-f-bombs-back">trying to blackmail him</a>.
See Also: <a href="https://www.benzinga.com/news/24/07/39880470/elon-musk-pushes-back-optimus-timeline-says-teslas-humanoid-robot-will-hopefully-be-available-for-ot?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Pushes Back Optimus Timeline, Says Tesla&#8217;s Humanoid Robot Will &#8216;Hopefully&#8217; Be Available For Other Companies By 2026</a>
Despite the potential risks, Musk has a history of taking public stands on issues such as free speech, and it remains to be seen how this latest incident will affect Tesla&#8217;s business in China.
Tesla did not immediately respond to&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga</a>'s request for comment.
Why It Matters: Musk&#8217;s recent post is not an isolated incident. Over the weekend, Musk shared an AI-generated video featuring global figures like Mark Zuckerberg in a reptilian skin suit, <a href="https://www.benzinga.com/news/24/07/39876926/elon-musk-says-its-high-time-for-an-ai-fashion-show-shares-video-of-mark-zuckerberg-in-a-reptile-sui">poking fun at conspiracy theories</a>. This video was part of an AI fashion show created by the YouTube channel "Interdimensional TV." 
Moreover, Tesla&#8217;s future in China is already under scrutiny. Analysts have <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39805672/will-tesla-robotaxis-be-allowed-in-china-analyst-says-highly-unlikely-investors-sho">raised concerns about the feasibility</a> of Tesla&#8217;s robotaxi technology in China due to national security risks. Morgan Stanley analyst Adam Jonas recently reiterated an Overweight rating on Tesla but noted significant uncertainties regarding its operations in China.
Tesla is also facing internal challenges in China. The company has been cutting jobs in the country amid increasing <a href="https://www.benzinga.com/news/large-cap/24/05/38733432/tesla-cuts-more-jobs-in-china-as-competition-heats-up">competition in the electric vehicle market</a>. Recent layoffs have affected various departments at Tesla&#8217;s Shanghai plant, which is responsible for over half of the company&#8217;s global production.
Meanwhile, Tesla is preparing to report its <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39892255/tesla-q2-earnings-preview-analyst-estimates-key-items-to-watch-can-major-turning-po">second-quarter financial results</a>. Analysts expect Tesla to report second-quarter revenue of $24.93 billion, according to data&nbsp;<a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072224&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">from Benzinga Pro.</a>
Price Action: Tesla stock closed at $251.51, up 5.15% on Monday. In after-hours trading, the stock increased slightly 0.04%. Year to date, Tesla&#8217;s stock has risen 1.24%, according to data <a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072224&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">from Benzinga Pro.</a>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39870321/tesla-ceo-elon-musk-blasts-satya-nadella-after-microsoft-crowdstrike-issue-takes-down-millions-of-co?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Tesla CEO Elon Musk Blasts Satya Nadella After Microsoft-CrowdStrike Issue Takes Down Millions Of Computers Globally: &#8216;This Gave A Seizure To The Automotive Supply Chain&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Kaustubh-Bagalkote" target="_blank" rel="noreferrer noopener">Kaustubh Bagalkote</a>

Equities

Elon Musk Posts AI Video Featuring Xi Jinping With Controversial Winnie The Pooh Reference: Will it Harm Tesla's Business In China?

Pfizer/GSK Owned ViiV Healthcare Announces Data For Dovato Which Is As Effective As 3-Drug Regimen Of Gilead's Biktarvy For Maintenance Therapy Of HIV-1

Earnings

KB Financial Q2 Profit Attributable To Controlling Interests WON1,710.8B (+65.1% QoQ); Net Interest Income WON3,206.2B (+1.7% QoQ)

MAIA Biotechnology, Inc., (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAIA#NYSE">MAIA</a>)&nbsp;(&quot;MAIA&quot;, the &quot;Company&quot;), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announces positive treatment updates from its Phase 2 clinical trial, THIO-101, evaluating THIO sequenced with the immune checkpoint inhibitor (CPI) cemiplimab (Libtayo&reg;) in patients with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care therapy regimens.
The trial&#39;s therapeutic regimen is cycled every 3 weeks, with THIO 180mg administered in 60mg incremental doses on days 1, 2 and 3, followed by immune activation on day 4 (no dosing), and cemiplimab 350mg administered on day 5. As of the latest clinical cutoff date, June 12, 2024:
<ul>
<li>6 patients remain on treatment following at least 12 months of therapy.</li>
<li>Treatment with THIO followed by cemiplimab has been well tolerated throughout the trial, with much lower toxicity compared to standard-of care treatments.</li>
<li>Continuing treatment past 12 months demonstrates safety, efficacy and ongoing benefit from MAIA&#39;s novel telomere targeting NSCLC therapy.</li>
</ul>
&quot;Our longest treated patient so far has completed 21 cycles of THIO sequenced with a CPI, and 6 patients who have crossed the 12-month survival follow-up are continuing the treatment,&quot; said Vlad Vitoc, M.D., Chairman and Chief Executive Officer of MAIA. &quot;With current therapies, second-line patients&#39; treatment duration is usually around 3-4 months1&nbsp;and third-line is even lower than that. It is very encouraging to see that our patients can remain on treatment for much longer. The ongoing benefits of THIO in longer-term patients are particularly notable, signifying THIO&#39;s potential as a durable and efficacious treatment for advanced NSCLC patients faced with limited options.&quot;
<ol>
<li><a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.sciencedirect.com%2Fscience%2Farticle%2Fpii%2FS0169500217304373&amp;esheet=54097974&amp;newsitemid=20240723808500&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.sciencedirect.com%2Fscience%2Farticle%2Fpii%2FS0169500217304373&amp;index=1&amp;md5=b49864acdcc39be65cbb0686e24c0b97">https://www.sciencedirect.com/science/article/pii/S0169500217304373</a></li>
</ol>
About THIO
THIO (6-thio-dG or 6-thio-2&#39;-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2&#39;-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type&ndash;specific immune memory. THIO is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.
About THIO-101, a Phase 2 Clinical Trial
THIO-101 is a multicenter, open-label, dose finding Phase 2 clinical trial. It is the first trial designed to evaluate THIO&#39;s anti-tumor activity when followed by PD-(L)1 inhibition. The trial is testing the hypothesis that low doses of THIO administered prior to cemiplimab (Libtayo&reg;) will enhance and prolong immune response in patients with advanced NSCLC who previously did not respond or developed resistance and progressed after first-line treatment regimen containing another checkpoint inhibitor. The trial design has two primary objectives: (1) to evaluate the safety and tolerability of THIO administered as an anticancer compound and a priming immune activator (2) to assess the clinical efficacy of THIO using Overall Response Rate (ORR) as the primary clinical endpoint. Treatment with cemiplimab (Libtayo&reg;) followed by THIO has been generally well-tolerated to date in a heavily pre-treated population. For more information on this Phase II trial, please visit ClinicalTrials.gov using the identifier NCT05208944.

MAIA Biotechnology Reports Phase 2 Results for Lung Cancer Treatment THIO

The EU has put&nbsp;Meta Platforms Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) on <a href="https://www.benzinga.com/news/24/07/39569000/metas-pay-or-consent-model-to-draw-charges-from-eu-report">notice over its &#8220;pay or consent&#8221;&nbsp;model</a> for Facebook and Instagram, citing potential violations of consumer protection laws.
What Happened: The EU&#8217;s Consumer Protection Cooperation or CPC Network has given Meta until Sept. 1, 2024, to propose changes to its <a href="https://www.benzinga.com/news/24/02/37390643/consumer-watchdogs-target-metas-pay-or-give-up-privacy-tactic-in-eu-smokescreen-to-obscure-illegal-d">&#8220;pay or consent&#8221; model</a>, according to a blog post on Tuesday.
The EU has labeled the model as &#8220;misleading&#8221; and &#8220;confusing&#8221; for users, and non-compliance could lead to fines.
&#8220;Consumer protection authorities assessed several elements that could constitute misleading or aggressive practices, in particular, whether Meta provided consumers upfront with true, clear, and sufficient information,&#8221; the union stated.
See Also:&nbsp;<a href="https://www.benzinga.com/news/24/07/39881748/elon-musks-xai-flips-the-switch-on-100k-nvidia-h100-gpus-worth-up-to-4b-in-memphis-supercluster-most?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk&#8217;s xAI Flips The Switch On 100K Nvidia H100 GPUs Worth Up To $4B In Memphis Supercluster: &#8216;Most Powerful AI Training Cluster In The World&#8217;</a>
Meta&#8217;s &#8220;pay or consent&#8221; model, rolled out last year, presents users with two choices: pay up to €12.99 (approximately $14.13) per month for ad-free usage of Facebook and Instagram or agree to the collection and use of personal data for personalized ads.
The CPC initiated its investigation in response to complaints from consumer watchdog groups. These groups alleged that Meta employs confusing language to describe the paid and &#8220;free&#8221; versions of its platforms.
Meta did not immediately respond to <a href="https://pro.benzinga.com/dashboard">Benzinga&#8217;s</a> request for comments.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters: This development follows <a href="https://www.benzinga.com/government/24/03/37828545/meta-bows-down-to-eu-regulations-after-apple-and-google-cut-subscription-prices-for-ad-free-facebook">Meta&#8217;s decision to reduce the subscription</a> fee for its ad-free Facebook and Instagram services in Europe to €5.99 ($6.5) from the initial €9.99 ($10.9).
This move was aimed at addressing growing concerns of privacy and antitrust regulators.
Last month, Meta faced a&nbsp;<a href="https://www.benzinga.com/news/24/06/39307741/meta-platforms-under-fire-in-norway-for-using-private-user-data-from-facebook-instagram-for-ai-train">complaint&nbsp;in Norway for using user images</a> and posts from Facebook and Instagram to train AI models. 
The Norwegian Consumer Council argued that the opt-out process violates strict EU data protection laws and that Meta uses deceptive design patterns and vague language to make opting out difficult.
Check out more of Benzinga&#8217;s Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39873131/apple-skips-tsmcs-2nm-chip-for-iphone-17-unveils-first-ios-18-public-beta-and-more-this-week-in-appl?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Apple Skips TSMC&#8217;s 2nm Chip For iPhone 17, Unveils First iOS 18 Public Beta And More: This Week In Appleverse</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Social Media

Meta Says Facebook Is 'Free' — EU Threatens To Fine Mark Zuckerberg-Led Social Media Giant

Helix Biopharma GAAP EPS of -C$0.03

Helix Biopharma GAAP EPS of -$0.01

Helix BioPharma

By <a href="https://scr.zacks.com/analyst-bios/person-details/default.aspx?ItemId=dd01b998-53e1-4448-9b1a-8fe0a6a3c606">John Vandermosten, CFA</a>

<stock_ticker>TSX:HBP.TO</stock_ticker> &#x7C; <stock_ticker>OTC:HBPCF</stock_ticker>

<a href="https://s27.q4cdn.com/906368049/files/News/2021/Zacks_SCR_Research_06182021_T.HBP_Vandermosten.pdf">READ THE FULL HBP.TO RESEARCH REPORT</a>

Helix BioPharma Corp. (TSX:<a class="ticker" href="https://www.benzinga.com/stock/HBP#TSX">HBP</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/HBPCF#OTC">HBPCF</a>) <a href="https://www.helixbiopharma.com/helix-biopharma-corp-announces-fiscal-third-quarter-2021-results/">reported</a> 3Q:21 financial and operational results and <a href="https://www.sedar.com/DisplayCompanyDocuments.do?lang=EN&issuerNo=00007600">submitted</a> its SEDAR filings on June 14, 2021. During 3Q:21, the three months ended April 30, 2021, Helix appointed Dr. Frank Gary Renshaw to the Scientific Advisory Board, and extended the exercise period for certain warrants among other activities. Following the end of the quarter, the company raised additional capital to support operations and the LDOS006 study. 

Financial results for the three months ended April 30, 2021 compared to the three months ended April 30, 2020 included:1

 ➢ Research and development expenses were $1.9 million, up 27% from $1.5 million, reflecting an increase in collaborative research spend associated with ProMab CAR-T, slightly higher L-DOS47 clinical program cost and increased amounts for intellectual property expenditures. These increases were partially offset by lower contract manufacturing activity; 
 ➢ Operating, general and administrative expenses were $651,000, down 24% from $862,000 on lower stock-based compensation and lower investor relations expenses partly offset by higher legal expenses;
 ➢ Income from finance items was $30,000 versus ($11,000), largely driven in both periods by fluctuations in foreign exchange;
 ➢ Loss from discontinued operations was $0 versus a gain of ($198,000);
 ➢ Net loss was ($2.6) million or ($0.02) per share vs. ($2.5) million and ($0.02) per share on a weighted average share count of 141.1 million shares and 130.6 million shares respectively.

As of April 30, 2021, cash stood at $2.3 million and there was no debt on the balance sheet. Cash levels do not include proceeds from the $3.5 million gross capital raise closed in mid-May. Cash burn for the three and nine months ending April 30, 2021 was ($1.8) million and ($7.5) million. Company management estimates that $25 million will be required to advance planned clinical and preclinical research and development activities until FY:23. The company plans to list on a new exchange in the United States and is in discussions with financers to conduct a capital raise in conjunction with the new listing. 

Convertible Security Funding Agreement

On May 10, 2021, Helix <a href="https://www.helixbiopharma.com/wp-content/uploads/2021/05/20210511-HBP-Press-Release-LIND-Final.pdf">entered</a> into a convertible security funding agreement with <a href="http://www.thelindpartners.com/cgi-bin/index.pl">Lind Global Macro Fund</a>. The effort raised $3.5 million in the initial tranche of the agreement and another $6.5 million may be raised in a second round. The convertibles have a two year term and accrue interest at a rate of 8.75% per annum with interest added to the principle of the security, resulting in a maturity value of $4,112,500. Helix will pay an additional 3% commitment fee to Lind at the closing of each tranche. 

Conversion of the securities may occur during its term at a conversion price equal to 85% of the average share price prior to conversion with a limit on the amount that may be converted every month. Two-thirds of the securities may be repurchased for cash by Helix if desired with no penalty. Other terms apply and are outlined in the agreement. 

Approximately two million warrants will be issued to Lind with a four year duration and exercise price of ~$1.03. Additional warrants related to the second tranche may also be issued with the number calculated under a complex formula that would yield approximately 3.5 to 3.6 million warrants with an exercise price of $0.90 to $1.05 based on recent price moves and on the closing of the $6.5 million in additional funding. 

Pipeline

The LDOS001 trial in the United States investigated L-DOS47 in combination with carboplatin and pemetrexed for non-small cell lung cancer (NSCLC). Topline data were presented at the American Society of Clinical Oncology (ASCO) conference this year. Additional reports have been completed for pharmacokinetics and immunogenicity; tables, listings and figures are expected to be available in June 2021. The clinical study report is now being developed and should be available in 3Q:21. Below we provide a summary of the study results.

<img src="https://www.benzinga.com//s27.q4cdn.com/906368049/files/pictures/2021/06232021_HBP_1.png" style="width: 550px;" />

The LDOS003 trial investigating the benefit of L-DOS47 with a combination of vinorelbine and cisplatin for non-small cell lung cancer (NSCLC) patients has been completed, pending close-out activities. This trial will not progress unless a partner is found. A report is being developed for the study that may be available in 2021; however, it has been delayed due to a disagreement between the company and clinical research organization (CRO).

Helix' pancreatic cancer trial, <a href="https://www.clinicaltrials.gov/ct2/show/NCT04203641?term=NCT04203641&draw=2&rank=1">LDOS006</a>, was launched in December 2019. As of June 2021, nine patients have been dosed, six of whom were dosed under the original protocol where patients were initiated on L-DOS47 in combination with 20 mg/m2 doxorubicin. Three subjects withdrew due to disease progression prior to completing the required 4-week cycle in order to be included in the evaluation for dose escalation. One of the remaining three patients experienced a dose limiting toxicity (DLT) attributed to doxorubicin, which required a protocol amendment. The amendment required a reduction in the chemotherapy dose. 

The amended protocol requires a reduced starting dose of 15 mg/m2 of doxorubicin and three patients were dosed under this regimen. One of three patients dosed under the 15 mg protocol experienced a serious adverse thromboembolic event. The investigator classified this as possibly related to L-DOS47 and alternatively related to the patient's prior medical history of thromboembolic events and advanced stage of pancreatic cancer. The sponsor physician assessed the event as possibly related to doxorubicin chemotherapy, patient's prior medical history, and uncontrolled pancreatic cancer state, although possible relationship to L-DOS47 in combination with doxorubicin could not be ruled out. As there were two DLTs, another cohort expansion of three patients is required. If a third DLT occurs, the current plan will stop and a study design revision will be required. 

Due to slower enrollment related to challenges resulting from the pandemic, an additional two sites have been activated. On March 12, 2021, Helix added one new study site and one other at the end of April to achieve completion of targeted enrollment before year end 2021.

Most of the patients initially considered for the Phase Ib did not complete the safety cycle due to the late stage of their illness. Following enrollment in the Phase Ib portion, which is expected to complete in 3Q:21, Helix will progress to the 11-patient Phase II segment of the study. The Phase II portion of the study will focus on anti-tumor activity in the anticipated 11 patients. The subjects will be dosed with L-DOS47 in combination with 15 mg/m2 doxorubicin3 with tumor marker measurements and radiological assessments every two treatment cycles. 

<img src="https://www.benzinga.com//s27.q4cdn.com/906368049/files/pictures/2021/06232021_HBP_2.png" style="width: 600px;" />

Corporate Milestones (Calendar Quarters Used)

 ➢ LDOS001 PK and immunogenicity reports – 2Q:21
 ➢ LDOS002 manuscript submitted to Journal of Thoracic Oncology – 2Q:21
 ➢ LDOS006 Phase Ib, last patient enrolled – 2H:21
 ➢ LDOS001 clinical study report – 2H:21
 ➢ Completion of LDOS003 clinical study report – 2021
 ➢ Capital raise of and uplisting OTC - 2021
 ➢ IND submission for L-DOS47 + chemo in lung cancer – December 2021
 ➢ Initiation of Phase II portion of LDOS006 – 2022
 ➢ NSCLC Phase II Clinical Study (L-DOS47 + immunotherapy) – 2021/2022
 ➢ LDOS006 Phase III Launch – 2022/2023
 ➢ Target pancreatic cancer with L-DOS47 in combination therapy - 2023

<img src="https://www.benzinga.com//s27.q4cdn.com/906368049/files/pictures/2021/06232021_HBP_3.png" style="width: 600px;" />
 
Summary

Since our second quarter update in March, Helix has raised additional capital, activated two new sites and dosed two additional patients under the new protocol in the LDOS006 trial. The company has also announced its intent to submit an IND to the FDA for L-DOS47 in combination with chemotherapy for lung cancer. Based on the current status of LDOS006, the last patient for the Phase Ib is expected to be enrolled in 2H:21 and the Phase II is anticipated to begin in calendar year 2022.

Helix raised additional capital to cover near term expenses while it is pursuing a listing on a US exchange in conjunction with a capital raise that would support the LDOS006 program and the move of the lung cancer program into the clinic if the proposed IND is cleared. With the additional capital and two new sites actively adding patients, we expect Helix to achieve its proposed timelines. 

<a href="http://scr.zacks.com/Subscribe/defaultaspx/ default.aspx" style="color: rgb(242, 132, 16); text-size-adjust: auto;">SUBSCRIBE TO ZACKS SMALL CAP RESEARCH</a> to receive our articles and reports emailed directly to you each morning. Please visit our <a href="http://scr.zacks.com/Home/default.aspx" style="color: rgb(242, 132, 16); text-size-adjust: auto;">website</a> for additional information on Zacks SCR.  DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $40,000 annually for these services. Full Disclaimer <a href="https://scr.zacks.com/home/default.aspx" style="color: rgb(242, 132, 16);">HERE</a>.

________________________ 

1. All currency in this report is denominated in Canadian Dollars unless otherwise noted. 
2. Source: Helix Biopharma 1Q:21 SEDAR Filing, Management Discussion and Analysis. 
3. This was reduced from 20 mg/m2 as a result of the protocol change.
4. Source: Helix Biopharma January 2021 Corporate Presentation. 
5. Source: Helix Biopharma 3Q:21 SEDAR Filing, Management Discussion and Analysis.

By <a href="http://scr.zacks.com/Analysts/Person-Details/default.aspx?ItemId=5f5b4009-a7d9-4228-af7d-5f721cbc93c2">John Vandermosten, CFA</a>

<stock_ticker>TSX:HBP.TO</stock_ticker> &#x7C; <stock_ticker>OTC:HBPCF</stock_ticker> 

<a href="https://s1.q4cdn.com/460208960/files/News/2020/Zacks_SCR_Research_12222020_T.HBP_Vandermosten.pdf">READ THE FULL HBP.TO RESEARCH REPORT</a>

First Quarter Fiscal Year 2021 Operational and Financial Results Helix BioPharma Corp. (TSX:<a class="ticker" href="/stock/HBP#TSX">HBP</a>) (OTC:<a class="ticker" href="/stock/HBPCF#OTC">HBPCF</a>) <a href="https://www.helixbiopharma.com/wp-content/uploads/2020/12/HBP-Q1F2021-Press-Release-FINAL.pdf">reported</a> first quarter fiscal year 2021 financial and operational results and <a href="https://www.sedar.com/DisplayProfile.do?lang=EN&issuerType=03&issuerNo=00007600">submitted</a> SEDAR filings on December 15, 2020.  During 1Q:21, extending from August 1 to October 31, 2020, Helix extended its collaboration agreement with Moffitt Cancer Center and executed a definitive agreement to divest Helix Immuno-Oncology (HIO).  The LDOS006 Phase Ib/II clinical trial for metastatic pancreatic adenocarcinoma has dosed seven patients and one has presented a chemotherapy-related dose limiting toxicity, triggering the obligatory enrollment of three additional patients.  Following the end of the quarter, Helix closed a private placement generating gross proceeds of $1.1 million.1

Operating expenses for the first quarter increased both sequentially and compared to the prior year and a gain related to the divestiture of HIO materially improved reported earnings.  Financial results for the three months ended October 31, 2020 compared to the three months ended October 31, 2019 included:2

‣ Expenses for R&D were $1.1 million, down 25% from $1.4 million, the result of lower clinical operation expense, intellectual property maintenance cost and collaborative scientific research expenditure;

‣ Operating G&A expenses were $1.3 million, up 126% from $0.6 million, due to higher legal costs, investor relations expenditures and audit fees;

‣ Unique to 1Q:21 was a $2.2 million gain related to the loss of control over HIO;3

‣ Cash burn totaled ($2.8) million, improving from ($4.6) million.

As of October 31, 2020, cash stood at $1.4 million, compared to $4.2 million at the end of FY:20. Following the end of the quarter, additional cash related to the HIO divestiture and the private placement closed on December 7th was added to the balance sheet resulting in a cash balance of approximately $4.7 million as of mid-December.

The company continues with no debt on its balance sheet.  Based on the cash balance and anticipated ~$2 to $3 million in quarterly cash burn, we anticipate a near term financing.  Helix plans to list on the NASDAQ market next year and is in discussions with financers to conduct a capital raise for $15 to $20 million in conjunction with the new listing.

Corporate Milestones

‣ IND clearance by FDA for LDOS006 – August 2019

‣ Launch of LDOS006 study – December 2019

‣ Full divestiture of HIO – November 2020

‣ $1.1 million private placement – December 2020

‣ Availability of additional supply of L-DOS47 – Fall / Winter 2020

‣ Anticipated enrollment completion of LDOS006 Phase Ib –2Q:21

‣ LSDOS001 Phase I finalized clinical study report – April 2021

‣ Capital raise of $15 to $20 million and uplisting to NASDAQ – 2021

‣ LDOS006 Phase II last patient enrolled – 4Q:21

‣ Completion of LDOS003 clinical study report - 2021

‣ LDOS006 Phase III Launch – 2H:22

Polish Subsidiary

On June 26, 2020, Helix <a href="https://www.helixbiopharma.com/wp-content/uploads/2020/06/20200626-HBP-Press-Release-HIO-divestiture.pdf">announced</a> that it would be divesting its remaining ownership in its Polish subsidiary, Helix Immuno-Oncology S.A. (HIO).  At the time of the announcement, Helix held a 51% interest in the entity following the sale earlier in the year of a 15.5% ownership stake.  HIO had been developing V-DOS47, an antibody protein conjugate that targets vascular endothelial growth factor 2 receptor (VEGFR2) that is expressed in many carcinomas and lymphomas.  Following the end of the reporting period, Helix cancelled approximately $2.7 million in intercompany debt owed to it by HIO.  Assets related to Biphasix and V-DOS47 were transferred back to Helix.  An increase in share capital was <a href="https://www.helixbiopharma.com/wp-content/uploads/2020/07/HELIX-Q3F2020-PressRelease-ver-Jul30-FINAL.pdf">approved</a> for HIO in early July, which allowed for 2.2 million shares to be issued raising gross proceeds of approximately 3 million Polish zloty.  This action reduced Helix' interest in HIO to 42.5%.  The company also accepted a non-binding offer to purchase the remaining interest for 6.7 million Polish zloty, equivalent to $2.3 million with CAIAC Fund Management AG.  The transaction was originally scheduled to close on August 31, 2020 but was delayed due to coronavirus related issues.  On November 9th, Helix <a href="https://www.helixbiopharma.com/wp-content/uploads/2020/11/20201109-HBP-Press-Release-HIO-divestiture.pdf">announced</a> that it had signed a definitive agreement to fully divest the subsidiary.  Following closing requirements, Helix will recognize 5.9 million Polish zloty (~$2 million) after transaction costs.  On December 23, the transaction was <a href="https://www.helixbiopharma.com/wp-content/uploads/2020/12/20201222-HBP-Press-Release-HIO-Closes-HIO-Divestiture.pdf">finalized</a> and payment was recognized.

Private Placement

On December 7, 2020, Helix <a href="https://www.helixbiopharma.com/wp-content/uploads/2020/12/Helix-PR-12042020.pdf">announced</a> the closing of a private placement with gross proceeds of $1.1 million.  The terms of the placement were for the purchase of units at $0.50 per unit, each unit comprising one common share and one common share purchase warrant.  Each common share purchase warrant will be exercisable at $0.70 with expiration in five years.

Pipeline

The LDOS001 trial in the United States investigated L-DOS47 in combination with carboplatin and pemetrexed for non-small cell lung cancer (NSCLC).  Topline data were presented at the American Society of Clinical Oncology (ASCO) conference this year.  The clinical study report is now being developed and should be available in the first part of 2021.  Below we provide a summary of the study results.

<img src="https://www.benzinga.com//s1.q4cdn.com/460208960/files/pictures/2020/Screen-Shot-2020-12-28-at-7.42.27-AM.png" alt="" style="width: 726px;" />

The LDOS003 trial investigating the benefit of L-DOS47 with a combination of vinorelbine and cisplatin for non-small cell lung cancer (NSCLC) patients has been completed, pending close out activities.  This trial will not progress unless a partner is found. A report is being developed for the study that will likely be available in 2021.

Helix' pancreatic cancer trial, <a href="https://www.clinicaltrials.gov/ct2/show/NCT04203641?term=NCT04203641&draw=2&rank=1">LDOS006</a>, was launched in December 2019.  As of December 2020, seven patients have been dosed, three of whom withdrew due to disease progression prior to completing the required 4-week cycle in order to be included in the evaluation for dose escalation.  One patient experienced a chemotherapy-related dose limiting toxicity and as a result, three additional patients will need to be enrolled to close the first cohort.  Due to slower enrolment related to challenges resulting from the pandemic, an additional two sites are engaged in study start-up activities, with plans to be open for patient recruitment in 1Q:21.  A protocol amendment is also planned for submission to FDA in December 2020.

Most of the patients initially considered for the Phase Ib did not complete the safety cy¬cle due to the late stage of their illness.  Following enrollment in the Phase Ib portion, which is expected to complete in 2Q:21, Helix will progress to the 11-patient Phase II segment of the study.  The Phase II portion of the study will focus on anti-tumor activity in the anticipated 11 patients.  The subjects will be dosed with L-DOS47 in combination with 20 mg/m2 doxorubicin with tumor marker measurements and radiological assessments every two treatment cycles.

<img src="https://www.benzinga.com//s1.q4cdn.com/460208960/files/pictures/2020/Screen-Shot-2020-12-28-at-7.43.09-AM.png" alt="" style="width: 720px;" />

<img src="https://www.benzinga.com//s1.q4cdn.com/460208960/files/pictures/2020/Screen-Shot-2020-12-28-at-7.43.52-AM.png" alt="" style="width: 740px;" />

Summary

Helix has streamlined its operations with the successful divestiture of the HIO asset which generated cash that can be used to advance the LDOS006 trial.  Helix also closed a $1.1 million private placement in December and continues talks with capital market firms targeting potential uplisting to the NASDAQ.  With the additional capital and the two new sites planned for the LDOS006 trial, we see an acceleration in enrollment by 1H:21 and continued advancement of the pancreatic indication.  The opportunity for L-DOS47 extends beyond the US and Europe and other programs in development provide additional opportunities to produce value.

<a href="http://scr.zacks.com/Subscribe/defaultaspx/default.aspx" style="color: rgb(242, 132, 16); font-family: HelveticaNeue; text-size-adjust: auto;">SUBSCRIBE TO ZACKS SMALL CAP RESEARCH</a> to receive our articles and reports emailed directly to you each morning. Please visit our <a href="http://scr.zacks.com/Home/default.aspx" style="color: rgb(242, 132, 16); font-family: HelveticaNeue; text-size-adjust: auto;">website</a> for additional information on Zacks SCR. 
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $40,000 annually for these services. Full Disclaimer <a href="http://scr.zacks.com/Disclaimer/default.aspx" style="color: rgb(242, 132, 16);">HERE</a>.

________________________ 

1. Amounts are denominated in Canadian dollars unless otherwise stated. 
2. The comparative period for the period ending October 31, 2019 was adjusted in the most recent filing to reflect the divestiture of HIO and adjustments related to "Right of Use Asset" accounting 
3. The gain is not amounts related to the full divestiture of HIO, which occurred subsequent to the end of the first quarter.
4. Source: Helix Biopharma 1Q:21 SEDAR Filing, Management Discussion and Analysis.
5. Source: Helix Biopharma August 2020 Corporate Presentation. 
6. Source: Helix Biopharma 1Q:21 SEDAR Filing, Management Discussion and Analysis

By <a href="http://scr.zacks.com/Analysts/Person-Details/default.aspx?ItemId=5f5b4009-a7d9-4228-af7d-5f721cbc93c2">John Vandermosten, CFA</a>

<stock_ticker>TSX:HBP.TO </stock_ticker> | <stock_ticker>OTC:HBPCF</stock_ticker>

<a href="https://s1.q4cdn.com/460208960/files/News/2020/Zacks_SCR_Research_03232020_T.HBP_Vandermosten.pdf">READ THE FULL HBP.TO RESEARCH REPORT</a>

Second Quarter 2019 Operational and Financial Results

Helix BioPharma Corp. (TSX:<a class="ticker" href="/stock/HBP#TSX">HBP</a>) (OTC:<a class="ticker" href="/stock/HBPCF#OTC">HBPCF</a>) <a href="http://www.helixbiopharma.com/wp-content/uploads/2020/03/20200316-HPR-PR-Q2Financials.pdf">reported</a> second quarter 2020 results and <a href="http://www.helixbiopharma.com/investors/">submitted</a> its SEDAR filings on March 16, 2020. The second quarter, which spanned the November 1 to January 31 period, saw the launch of the L-DOS47 pancreatic trial, participation in several investor conferences, and the close of multiple private placements to funds its research and development activities. 

Net loss for 2Q:20 was ($2.3) million1, an increase from the ($1.9) million loss in 2Q:19. On a per share basis this was ($0.02). Research and development expense was $1.6 million, up 19% from prior year levels due to greater expenditures on L-DOS47 including the launch of the pancreatic cancer study, and additional manufacturing costs for procuring additional drug product. Higher trademark and patent costs were also a contributor; however, there was no spend on the CAR-T program this year as there was in the prior period. General and administrative expenses were $654,000, rising 23% on increased expenditures for third party advisors and stock based compensation partially offset by lower wages and benefits.

As of January 31, 2020, the cash balance was $2.1 million compared to $0.2 million as of the end of the fiscal year, July 31, 2019. Cash burn in the second quarter was ($2.1) million, below prior year levels of ($2.4) million. Following the end of the reporting period, Helix raised an additional CAD$6 million which will continue to fund operations and research and development activities. The company has no debt on its balance sheet.

Helix is sponsoring two active Phase II trials. A combination chemotherapy trial for European and Asian markets and a monotherapy trial which has completed data collection and is now finalizing reports for non-small cell lung cancer (NSCLC). A Phase Ib/II pancreatic cancer trial was recently launched that is expected to read out in 2021. This latter trial, which is being conducted in Scottsdale, Arizona has two actively enrolled patients in the study. Two other patients had also been enrolled, however, prior to starting the experimental treatment, they no longer qualified for the trial and withdrew from the study. 

Drug Product

Helix recently contracted with a manufacturing organization to produce additional volumes of L-DOS47 for use in ongoing trials. Additional drug product is expected by the end of the summer. The product has already been manufactured and the polishing and fill and finish steps are now taking place. During the second quarter, approximately $295,000 was spent in this effort. 

Pipeline

Helix' pancreatic cancer trial, LDOS006, was launched in December and now has two enrollees in the Phase Ib portion of the study. This trial is combining chemotherapy agent doxorubicin with L-DOS47 in a dose escalating study for pancreatic cancer patients who have already undergone prior lines of therapy. The Phase Ib portion is targeting 9 patients for the study and will progress to the 11-patient Phase II segment of the study. 

The LDOS003 trial is also underway examining the benefit of L-DOS47 with a combination of vinorelbine and cisplatin for non-small cell lung cancer (NSCLC) patients. This trial has been on hold since 2018 due to a shortage of vinorelbine and as management awaits a partner to advance the work.

The LDOS001 trial is being conducted in the United States using L-DOS47 in combination with carboplatin and pemetrexed for NSCLC. Patient recruitment was closed mid-2019 and the trial is working on finalizing data for reporting. An abstract for trial outcomes has been submitted for presentation at American Society of Clinical Oncology (ASCO) conference this year. A clinical study report is expected by 1Q:20. 

<img src="https://www.benzinga.com//s1.q4cdn.com/460208960/files/pictures/2020/04062020_HBP_1.png" style="width: 650px; height: 283px;" />

Exhibit I – Product Development Pipeline2

Corporate Milestones

Below we list key milestones that have occurred in the last year and anticipated future events.

‣ IND clearance by FDA for LDOS006 – August 2019 

‣ Launch of LDOS006 – December 2019

‣ $6.0 million capital raise – March 2020

‣ Divestiture of 15.5% of Helix Immuno-Oncology (HIO) – March 2020

‣ LDOS001 abstract submitted – Calendar 1Q:20

‣ LDOS002 clinical study report under review – Calendar 1Q:20

‣ Availability of additional supply of L-DOS47 – 2H:20 

‣ Advancement of LDOS003 to Part II – Dependent on partnership 

‣ Anticipated completion of LDOS006 – year-end 2021

Investment Thesis

Helix is focused on modulating the acidic tumor microenvironment through the use of an antibody protein conjugate which links a epitope-specific antibody to a urease enzyme. The urease enzyme is able to catalyze extracellular urea into inert carbon dioxide and basic ammonia which raises the pH of the tumor microenvironment. The ammonia is toxic to cancer cells and also creates an environment that allows weak-base chemotherapies to come in closer contact with target cancer cells. Helix is currently pursuing indications in combination with chemotherapy for non-small cell lung carcinoma (NSCLC) and pancreatic cancer. There may be future opportunities for combination work with checkpoint inhibitors. Below we summarize the key elements supporting our favorable investment thesis. Refer to our <a href="https://s1.q4cdn.com/460208960/files/News/2020/Zacks_SCR_Research_01062020_T.HBP_Vandermosten.pdf">initiation</a> report for a details discussion of the company. 

Key reasons to own Helix shares:

‣ Novel mechanism of action that is synergistic with other therapies

‣ CEACAM6 target is specific to tumor cells, especially lung and pancreatic adenocarcinoma

‣ L-DOS47 may reverse acidic extra-cellular conditions favorable to cancer cell survival

‣ L-DOS47 may improve uptake of weak-base chemotherapeutics

‣ L-DOS47 may reduce PD-1 and PD-L1 expression thereby improving immune response

‣ Favorable drug safety profile with no reported drug-related adverse events

‣ Biologic eligible for 12 years of exclusivity in United States and extended protection in other geographies

‣ North American rights to intellectual property

‣ Pursuing multiple indications

	◦ Non small cell lung cancer

	◦ Pancreatic cancer

<a href="http://scr.zacks.com/Subscribe/defaultaspx/default.aspx" style="color: rgb(242, 132, 16); font-family: HelveticaNeue; text-size-adjust: auto;">SUBSCRIBE TO ZACKS SMALL CAP RESEARCH</a> to receive our articles and reports emailed directly to you each morning. Please visit our <a href="http://scr.zacks.com/Home/default.aspx" style="color: rgb(242, 132, 16); font-family: HelveticaNeue; text-size-adjust: auto;">website</a> for additional information on Zacks SCR. 
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $30,000 annually for these services. Full Disclaimer <a href="http://scr.zacks.com/Disclaimer/default.aspx" style="color: rgb(242, 132, 16);">HERE</a>.

_________________________

1. Share prices, value references in the text and financial statement items are denominated in Canadian dollars.

2. Source: Helix Biopharma February 2020 Corporate Presentation.

By <a href="http://scr.zacks.com/Analysts/Person-Details/default.aspx?ItemId=5f5b4009-a7d9-4228-af7d-5f721cbc93c2">John Vandermosten, CFA</a>

<stock_ticker>TSX:HBP.TO</stock_ticker> | <stock_ticker>OTC:HBPCF</stock_ticker>

<a href="https://s1.q4cdn.com/460208960/files/News/2020/Zacks_SCR_Research_01062020_T.HBP_Vandermosten.pdf">READ THE FULL HBP.TO RESEARCH REPORT</a>

INITIATING COVERAGE

We are initiating coverage of Helix BioPharma Corp. (TSX:<a class="ticker" href="/stock/HBP#TSX">HBP</a>) (OTC:<a class="ticker" href="/stock/HBPCF#OTC">HBPCF</a>) with a current valuation of CAD$2.001 per share. This present value is based on our estimates for continued development of L-DOS47 in phased trials and a 2026 global launch of L-DOS47 for non-small cell lung cancer (NSCLC) and pancreatic cancer in conjunction with partners. The clinical-stage company is developing its lead candidate, an enzyme conjugated to a monoclonal antibody (mAb) which can increase the pH of the tumor microenvironment (TME), to provide multiple beneficial effects against cancer. The construct is known as an antibody protein conjugate (APC) and is similar in composition to an antibody drug conjugate (ADC). The candidate is in Phase II studies for NSCLC and pancreatic cancer.

<img src="https://www.benzinga.com//s1.q4cdn.com/460208960/files/pictures/2020/01092020_HBP_1.png" style="width: 550px; height: 109px;" />

L-DOS47 links the enzyme urease to a mAb which can bind to a tumor marker appearing on lung and pancreatic cancer cells. When the mAb is bound to the tumor cell, the action of the linked enzyme is able to alter the pH of the TME by converting nearby urea into ammonia. The ammonia is cytotoxic to the tumor cells and causes a slight rise in the nearby pH potentially enhancing the efficacy of weak base chemotherapeutics. Preclinical work has also shown that the presence of L-DOS47 can reduce expression of the PD-L1 protein, enhancing the natural immune system's ability to recognize cancerous cells. The biologic is being developed as therapy in combination with chemotherapy or other immunotherapy in both indications. This approach aims to act against the tumor from multiple directions, enhancing the tumor fighting effect of chemotherapeutics and the natural immune system. While first line therapy is effective in some cases, most patients require second line, which maintains a sizable market in both settings for the APC if eventually found effective and approved. The possibility also exists that the agent may be appropriate for both first and later line treatments in various circumstances.

Helix is conducting several Phase II trials. A combination chemotherapy trial for European and Asian markets and a monotherapy trial which has completed data collection and is now finalizing reports for non-small cell lung cancer (NSCLC). A Phase Ib/II pancreatic cancer trial was recently launched that is expected to read out in 2021. 

On October 31, 2019, Helix held approximately $1.7 million in cash on its balance sheet following a $7.0 million capital raise. The availability of these funds has enabled Helix to launch its Phase Ib/II pancreatic cancer study with L-DOS47. However, additional funds will be required in the near term to continue research and development activities. The company currently holds no debt. We expect Helix to consume ~$600,000 in cash per month in 2020 as it advances its Phase II programs.

Based on our review, we anticipate that pivotal data will be available for indications NSCLC and pancreatic cancer by 2025. We expect a submission of a biologics license application (BLA) to regulatory authorities in the US and Europe and a response from the FDA and EMA over the 2025 to 2027 period with the first submission to the FDA in pancreatic cancer. Approval and commercialization are expected one year after submission based on historical precedents. If data from the trial demonstrate a major advance in treatment, Helix may receive a breakthrough or priority review designation, which would advance the drug more quickly through the application process. Pancreatic cancer is diagnosed in between 50 and 60 thousand persons per year which may qualify L-DOS47 for an Orphan Drug Designation.

Helix' innovative approach to addressing cancer has several synergies with chemotherapeutics, can precisely deliver cancer cell cytotoxicity to target cells and may enhance the body's immune response. We anticipate a near-term readout for the L-DOS47 monotherapy trial followed by interim readouts for the other studies in progress. The company needs a partner and continued financing to further advance L-DOS47 through 2020 and if data is supportive of continued work we anticipate a BLA submission and ultimate commercialization. 

INVESTMENT THESIS

A substantial body of research has shown that the tumor microenvironment becomes acidic as cancerous cells favor metabolism via glycolysis. The high metabolic demand of tumor cells' fermentation of glucose to lactic acid creates free H+ ions that lower the surrounding pH. As a result of low tissue perfusion due to defective vasculature the acidic environment is not thoroughly flushed with oxygenated blood. Cancer cells can adapt to survive in low pH environments through increased glycolytic activity and expression of proton transporters that normalize intracellular pH. However, the extracellular acidic tumor microenvironment has been shown to be immuno-suppressive. The lower pH inhibits T and natural killer (NK) cells and promotes myeloid derived suppressor cells and T regulatory cells. This lower pH not only increases immuno-suppression around the tumor but also can impact the effectiveness of cancer therapies such as checkpoint inhibitors and chemotherapy by producing an acidic shield around the TME. 

To address this imbalance, Helix has designed an elegant solution designated L-DOS47 that conjugates a tumor protein specific monoclonal antibody (mAb) with a urease enzyme to convert nearby urea into ammonia and carbon dioxide. The mAb targets carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6), which is expressed in numerous cancers, including NSCLC and pancreatic. The enzymatic reaction's ammonia production is toxic to tumor cells and also has the effect of increasing the pH, potentially reversing immuno-suppressive effects and allowing weak-base chemotherapeutics to work better. Helix has initiated two Phase II trials and has just begun a Phase Ib/II in pancreatic cancer which are evaluating lead candidate L-DOS47. 

L-DOS47's unique mechanism of action which both raises pH and creates a toxic environment for cancer cells is particularly amenable to combination therapy. Weak base chemotherapeutics such as vinorelbine may show synergistic efficacy with L-DOS47. The candidate may also reduce PD-L1 expression on tumor cells thereby enhancing T cell effectiveness. Studies have shown that raising intratumoral pH can improve responses to checkpoint blockade inhibitor immunotherapy.

Current standard of care for non-small cell lung carcinoma (NSCLC) is dominated by surgery, radiation therapy and chemotherapy; however, targeted therapy and immunotherapy are also appropriate. There are ~228,000 new US cases of lung and bronchus cancer expected in 2019, second in incidence only to breast cancer. NSCLC makes up a large portion of this population and is a particularly attractive indication for Helix as there are many cases that can be addressed. If proven safe and effective, L-DOS47 would be a prime candidate for combination therapy with checkpoint inhibitors in first line therapy or with chemotherapy in second line therapy. 

Pancreatic cancer is one of the most deadly cancers in large part due to the difficulty of early detection. Surgery radiation and chemotherapy may be appropriate for the disease when caught in its earlier stages; however, there are few effective treatments for most who are diagnosed with the disease. Pancreatic cancer makes up about 3% of all cancers which is equivalent to ~57,000 new cases per year in the United States. It is a desirable indication to pursue due to the lack of alternative therapies and the severe unmet need. The DOS47 platform may also be appropriate for other cancers. 

We take a conservative approach and anticipate the drug to have similar pricing as immunotherapies and oncology biologics in the United States. We expect a discount to these levels in other markets such as Europe and Asia. We make reductions for regions ex-US to reflect relative prices in these economic areas.

While our target price is generated based on L-DOS47 success in NSCLC and pancreatic cancer, Helix has several other assets in its portfolio including V-DOS47 and a chimeric antigen receptor (CAR)-T cell candidate. We anticipate adding a valuation component for these programs as they advance to a more mature stage. 

Key reasons to own Helix shares:

‣ Novel mechanism of action that is synergistic with other therapies

‣ CEACAM6 target is specific to tumor cells, especially lung and pancreatic adenocarcinoma

‣ L-DOS47 may reverse acidic extra-cellular conditions favorable to cancer cell survival

‣ L-DOS47 may improve uptake of weak-base chemotherapeutics

‣ L-DOS47 may reduce PD-1 and PD-L1 expression thereby improving immune response

‣ Favorable drug safety profile with no reported drug-related adverse events

‣ Biologic eligible for 12 years of exclusivity in United States and extended protection in other geographies

‣ North American rights to intellectual property

‣ Pursuing multiple indications

	◦ Non small cell lung cancer

	◦ Pancreatic cancer

In the following sections we review the oncology space and DOS47's position in it with a discussion of ADCs and their relationship to Helix' platform. We expect first sales in 2026 following favorable registrational data, the submission of a BLA and regulatory approval. We discuss the assumptions in our appraisal and generate a valuation of $2.00 per share. L-DOS47 may prove to be an excellent complement to chemotherapy and immunotherapy lending significant synergies through the precise mechanism of targeting and reducing the acidity in the tumor microenvironment. 

Targeted Therapies for Treating Cancer

Antibody Drug Conjugates

Antibody drug conjugates (ADCs) are monoclonal antibodies (mAbs) chemically attached to a biologically active cytotoxic payload or drug. mAbs are very specific in their targeting and allow the linked payload to be delivered to the desired site thereby limiting off target effects. The precise nature of ADCs allows the use of more potent toxins that would be prohibitive if used systemically. An important component of the ADC is the chemical linker that matches the payload with the mAb. The linker is designed to be either cleavable or non-cleavable, which determines the properties of the drug delivery. The linker also controls the distribution and delivery of the payload to the desired cell and can be designed to deliver the drug over an extended period. In most cases, after binding to surface antigens, ADCs are endocytosed into the cell where they undergo lysosomal degradation and release of their concentrated cytotoxic payload. There are a limited number of cytotoxic payloads that are sufficiently stable to make it to the inside of a cell. The most common attachments include microtubule inhibitors, DNA synthesis inhibitors and topoisomerase inhibitors. If the linked drug has the desired effect, it will cause cell apoptosis and eradicate the cancer.

Helix has introduced a variation on the ADC and maintains the epitope specific mAb and chemical linker, but instead of using a toxic payload, attaches a urease enzyme to create toxic ammonia at the surface of the cancer cell. This is known as an antibody protein conjugate (APC) which functions similarly to an ADC. The L-DOS47 unit developed by Helix consists of a camelid antibody employing a non-cleavable chemical linker to a urease enzyme. A feature differentiating the two structures is that the APC is not internalized into the target cell to release its payload while the ADC is taken inside. L-DOS47 is considered an immunotherapy due to its mechanism of action, which reverses immune system suppression due to acidosis.

Immuno-oncology

Immuno-oncology (IO), or cancer immunotherapy is an approach to fighting cancer that uses the body's own immune system to attack the disease. Normally, the body's immune system can eliminate cancer cells, but in some cases, these cells can adapt to hide and proliferate. When IO drugs or biologics are administered, they allow the immune system to recognize harmful cells and destroy them, in many cases with fewer and shorter-lived side effects compared to surgery, chemotherapy and radiotherapy. Immunotherapy is preferred because it is frequently associated with fewer adverse events, maintains its potency, works well in conjunction with other therapies and is also able to better target the disease. Several classes of immunotherapy exist including therapeutic vaccines, checkpoint inhibitors, immune modulators, adoptive cell therapy (CAR-T), antibody drug conjugates and oncolytic viruses among others. Immunotherapy is commonly used and enhanced by other approaches such as chemotherapy and antibody drug conjugates2. In recent years, many of the leading checkpoint inhibitors have advanced towards first line treatment of cancer, despite only working in a minority of cases. One of the goals of approved immunotherapies is to increase their effectiveness by combining with other drugs that enhance the ability of immune system to eradicate cancer. 

L-DOS47

L-DOS47 is Helix' first drug product candidate and has recently completed a Phase I/II monotherapy trial. The candidate is currently in a Phase I combination trial with carboplatin and pemetrexed in the United States and a Phase II combination trial with vinorelbine and cisplatin in Ukraine and Poland. The product was recently cleared by the FDA to launch a Phase Ib/II trial for advanced pancreatic cancer in the United States with enrollment and screening beginning in December 2019. 

L-DOS47 is an antibody protein conjugate (APC) which provides benefits as compared to other therapies. The candidate makes use of a camelid single domain antibody designated AFAIKL2 that can identify specific antigenic sites on cancer cells and precisely deliver the enzyme to the desired site. L-DOS47 is a chemical conjugate of a recombinant single domain antibody and Jack bean urease which can link multiple antibodies per urease molecule. The urease enzyme is derived and purified from the jack-bean plant, which produces beans that can be consumed by humans and animals, although it can be toxic if consumed to excess. Urease is extracted from the seeds of the plant by using a complex refining process, then is conjugated with an antibody by a chemical linker. After completion of manufacture and administration, the AFAIKL2 antibody binds with the CEACAM6 antigenic site expressed on certain cancer cells.

<img src="https://www.benzinga.com//s1.q4cdn.com/460208960/files/pictures/2020/01092020_HBP_2.png" style="width: 350px; height: 356px;" />

Antibodies Linked to Urease Enzyme3

Corporate Milestones

Helix is conducting multiple Phase II trials and is expected to provide a readout of the L-DOS47 monotherapy study in the first half of 2020. Below we list key milestones that have occurred in the last year and anticipated future events.

‣ IND clearance by FDA for LDOS006 – August 2019 ($6.4 mm to complete study)

‣ Final clinical study report for LDOS001 – Calendar 1Q:20 (will cost $627,000)

‣ Finalized clinical reports for LDOS002 – Calendar 1Q:20

‣ Completion of first (non-randomized) portion of LDOS003 - Calendar 1Q:20

‣ Advancement of LDOS003 to Part II – Dependent on partnership 

‣ Anticipated completion of LDOS006 – year-end 2021

‣ Availability of additional supply of L-DOS47 – Calendar 4Q:20 ($1.64 mm cost)

Conclusion

Helix has demonstrated early safety and efficacy in its lead candidate L-DOS47. The compound may enhance the efficacy of other cancer treatments using a novel mechanism of action that addresses acidosis. Please consult our initiation which provides additional detail regarding the targeted indications in NSCLC and pancreatic cancer, a review of preclinical and clinical work on L-DOS47 as well as a discussion of peers, risks and our valuation justification. 

<a href="http://scr.zacks.com/Subscribe/defaultaspx/default.aspx" style="color: rgb(242, 132, 16); font-family: HelveticaNeue; text-size-adjust: auto;">SUBSCRIBE TO ZACKS SMALL CAP RESEARCH</a> to receive our articles and reports emailed directly to you each morning. Please visit our <a href="http://scr.zacks.com/Home/default.aspx" style="color: rgb(242, 132, 16); font-family: HelveticaNeue; text-size-adjust: auto;">website</a> for additional information on Zacks SCR. 
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $30,000 annually for these services. Full Disclaimer <a href="http://scr.zacks.com/Disclaimer/default.aspx" style="color: rgb(242, 132, 16);">HERE</a>.

__________________________________

1. Share prices, value references in the text and financial statement items are denominated in Canadian dollars.

2. <a href="https://www.pharmoutsourcing.com/Featured-Articles/358918-The-Evolving-Shape-of-the-ADC-Market-The-Widening-Application-of-ADCs-and-Manufacturing-Improvements-Meeting-Demand/" title="https://www.pharmoutsourcing.com/Featured-Articles/358918-The-Evolving-Shape-of-the-ADC-Market-The-Widening-Application-of-ADCs-and-Manufacturing-Improvements-Meeting-Demand/">https://www.pharmoutsourcing.com/Featured-Articles/358918-The-Evolving-Shape-of-the-ADC-Market-The-Widening-Application-of-ADCs-and-Manufacturing-Improvements-Meeting-Demand/</a>

3. Source: Helix BioPharma Tumor Defence Breaker Video. <a href="http://www.helixbiopharma.com/" title="http://www.helixbiopharma.com/">http://www.helixbiopharma.com/</a>

HBP.TO: A New Approach to Enhance Standard of Care

This morning 89 companies reached new 52-week highs.

<h3>Things to Consider:</h3>

<ul>
	<li>PepsiCo (NASDAQ:<a class="ticker" href="/stock/PEP#NASDAQ">PEP</a>) was the largest firm on a market cap basis to set a new 52-week high.</li>
	<li>The smallest company when looking at market cap to set a new 52-week high was WOD Retail Solutions (OTC:<a class="ticker" href="/stock/WODI#OTC">WODI</a>).</li>
	<li>Dream Industrial REIT (OTC:<a class="ticker" href="/stock/DREUF#OTC">DREUF</a>)&#39;s stock actually sank the most, moving down 20.0% after reaching a new 52-week high.</li>
</ul>

Here are all the stocks that set new 52-week highs as of 10am on Friday:

<ul>
	<li>PepsiCo (NASDAQ:<a class="ticker" href="/stock/PEP#NASDAQ">PEP</a>) shares were up 0.91% on Friday morning to hit a new 52-week high of $139.76.</li>
	<li>Enel (OTC:<a class="ticker" href="/stock/ESOCF#OTC">ESOCF</a>) shares were up 3.18% on Friday morning to hit a new 52-week high of $7.48.</li>
	<li>Dominion Energy (NYSE:<a class="ticker" href="/stock/D#NYSE">D</a>) shares set a new 52-week high of $81.46 on Friday, moving up 1.48%.</li>
	<li>KDDI (OTC:<a class="ticker" href="/stock/KDDIY#OTC">KDDIY</a>) shares hit $13.82 on Friday morning, setting a new 52-week high for a change of up 1.08%.</li>
	<li>Edwards Lifesciences (NYSE:<a class="ticker" href="/stock/EW#NYSE">EW</a>) shares hit $228.31 on Friday morning, setting a new 52-week high for a change of up 2.19%.</li>
	<li>Equity Residential (NYSE:<a class="ticker" href="/stock/EQR#NYSE">EQR</a>) stock on Friday broke to a yearly high of $87.26. Shares traded up 0.34%.</li>
	<li>AvalonBay Communities (NYSE:<a class="ticker" href="/stock/AVB#NYSE">AVB</a>) shares were down 0.03% for the day, having made a 52-week high of $218.50.</li>
	<li>Digital Realty Trust (OTC:<a class="ticker" href="/stock/DLRTP#OTC">DLRTP</a>) shares were flat% on Friday morning to hit a new 52-week high of $25.15.</li>
	<li>Dollar Tree (NASDAQ:<a class="ticker" href="/stock/DLTR#NASDAQ">DLTR</a>) shares hit a new 52-week high of $115.79. The stock traded up 2.48% on the session.</li>
	<li>Realty Income (NYSE:<a class="ticker" href="/stock/O#NYSE">O</a>) stock set a new 52-week high of $78.05 Friday morning. Over the session, the stock traded up 0.31%.</li>
	<li>Adyen (OTC:<a class="ticker" href="/stock/ADYEY#OTC">ADYEY</a>) shares broke to a new 52-week high of $13.15 on Friday. Shares of the company traded up 1.39%.</li>
	<li>Brookfield Prop Partners (NASDAQ:<a class="ticker" href="/stock/BPYPO#NASDAQ">BPYPO</a>) stock made a new 52-week high of $26.00 Friday. The stock was up 0.23% for the day.</li>
	<li>Ansys (NASDAQ:<a class="ticker" href="/stock/ANSS#NASDAQ">ANSS</a>) stock set a new 52-week high of $224.00 Friday morning. Over the session, the stock traded up 1.8%.</li>
	<li>Lennar (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/len-b#NYSE">LEN-B</a>) shares broke to $59.27 on Friday, setting a new 52-week high with a change of up 2.1%.</li>
	<li>Lennar (NYSE:<a class="ticker" href="/stock/LEN#NYSE">LEN</a>) stock hit a yearly high price of $46.92. The stock was up 1.83% for the day.</li>
	<li>HCP (NYSE:<a class="ticker" href="/stock/HCP#NYSE">HCP</a>) shares set a new yearly high of $36.46 this morning. The stock was down 0.32% on the session.</li>
	<li>Olympus (OTC:<a class="ticker" href="/stock/OCPNY#OTC">OCPNY</a>) shares broke to $13.73 on Friday, setting a new 52-week high with a change of up 1.67%.</li>
	<li>Anglo American Platinum (OTC:<a class="ticker" href="/stock/AGPPF#OTC">AGPPF</a>) stock hit a yearly high price of $69.00. The stock was up 0.15% for the day.</li>
	<li>Invitation Homes (NYSE:<a class="ticker" href="/stock/INVH#NYSE">INVH</a>) shares were up 0.15% on Friday morning to hit a new 52-week high of $30.06.</li>
	<li>EDP - Energias (OTC:<a class="ticker" href="/stock/EDPFY#OTC">EDPFY</a>) stock made a new 52-week high of $39.90 Friday. The stock was up 2.26% for the day.</li>
	<li>Sun Communities (NYSE:<a class="ticker" href="/stock/SUI#NYSE">SUI</a>) shares were up 0.5% on Friday morning to hit a new 52-week high of $151.89.</li>
	<li>Sekisui House (OTC:<a class="ticker" href="/stock/SKHSY#OTC">SKHSY</a>) shares set a new yearly high of $20.10 this morning. The stock was up 1.28% on the session.</li>
	<li>Bangkok Dusit Medical (OTC:<a class="ticker" href="/stock/BDUUF#OTC">BDUUF</a>) shares were up 9.59% on Friday to hit a new 52-week high of $0.80 for a change of up 9.59%.</li>
	<li>Duke Realty (NYSE:<a class="ticker" href="/stock/DRE#NYSE">DRE</a>) shares were up 0.25% for the day, having made a 52-week high of $34.28.</li>
	<li>Camden Prop Trust (NYSE:<a class="ticker" href="/stock/CPT#NYSE">CPT</a>) shares were up 0.37% on Friday to hit a new 52-week high of $112.59 for a change of up 0.37%.</li>
	<li>RingCentral (NYSE:<a class="ticker" href="/stock/RNG#NYSE">RNG</a>) stock hit a yearly high price of $146.47. The stock was up 25.31% for the day.</li>
	<li>PulteGroup (NYSE:<a class="ticker" href="/stock/PHM#NYSE">PHM</a>) shares were up 2.0% on Friday morning to hit a new 52-week high of $36.73.</li>
	<li>Proximus (OTC:<a class="ticker" href="/stock/BGAOF#OTC">BGAOF</a>) shares broke to a new 52-week high of $30.24 on Friday. Shares of the company traded up 4.1%.</li>
	<li>Orkla (OTC:<a class="ticker" href="/stock/ORKLY#OTC">ORKLY</a>) shares set a new 52-week high of $9.33 on Friday, moving up 3.07%.</li>
	<li>Omega Healthcare (NYSE:<a class="ticker" href="/stock/OHI#NYSE">OHI</a>) shares reached a new 52-week high of $42.26 on Friday morning, moving up 0.43%.</li>
	<li>Apartment Inv &amp; Mgmt (NYSE:<a class="ticker" href="/stock/AIV#NYSE">AIV</a>) shares hit a yearly high of $52.77. The stock traded up 0.71% on the session.</li>
	<li>Douglas Emmett (NYSE:<a class="ticker" href="/stock/DEI#NYSE">DEI</a>) stock made a new 52-week high of $43.07 Friday. The stock was up 0.23% for the day.</li>
	<li>Flutter Entertainment (OTC:<a class="ticker" href="/stock/PDYPY#OTC">PDYPY</a>) stock made a new 52-week high of $50.95 Friday. The stock was up 2.31% for the day.</li>
	<li>Americold Realty Trust (NYSE:<a class="ticker" href="/stock/COLD#NYSE">COLD</a>) stock set a new 52-week high of $37.60 Friday morning. Over the session, the stock traded up 0.24%.</li>
	<li>Brookfield Renewable (NYSE:<a class="ticker" href="/stock/BEP#NYSE">BEP</a>) shares hit a yearly high of $41.59. The stock traded up 0.66% on the session.</li>
	<li>Algonquin Power (NYSE:<a class="ticker" href="/stock/AQN#NYSE">AQN</a>) shares were up 1.42% for the day, having made a 52-week high of $13.94.</li>
	<li>GCI Liberty (NASDAQ:<a class="ticker" href="/stock/GLIBA#NASDAQ">GLIBA</a>) shares set a new yearly high of $64.98 this morning. The stock was up 2.68% on the session.</li>
	<li>Square Enix Holdings (OTC:<a class="ticker" href="/stock/SQNNY#OTC">SQNNY</a>) stock made a new 52-week high of $23.16 Friday. The stock was up 17.09% for the day.</li>
	<li>Impala Platinum Holdings (OTC:<a class="ticker" href="/stock/IMPUY#OTC">IMPUY</a>) shares set a new yearly high of $6.92 this morning. The stock was up 2.1% on the session.</li>
	<li>Healthcare Realty Trust (NYSE:<a class="ticker" href="/stock/HR#NYSE">HR</a>) shares hit $33.90 on Friday morning, setting a new 52-week high for a change of down 0.61%.</li>
	<li>Outfront Media (NYSE:<a class="ticker" href="/stock/OUT#NYSE">OUT</a>) stock set a new 52-week high of $28.41 Friday morning. Over the session, the stock traded up 1.81%.</li>
	<li>Sibanye-Stillwater (NYSE:<a class="ticker" href="/stock/SBGL#NYSE">SBGL</a>) shares broke to a new 52-week high of $6.22 on Friday. Shares of the company traded up 3.4%.</li>
	<li>Bakkafrost (OTC:<a class="ticker" href="/stock/BKFKF#OTC">BKFKF</a>) shares broke to a new 52-week high of $61.00 on Friday. Shares of the company traded up 3.04%.</li>
	<li>Taiyo Yuden (OTC:<a class="ticker" href="/stock/TYOYY#OTC">TYOYY</a>) shares hit a new 52-week high of $102.00. The stock traded up 2.0% on the session.</li>
	<li>Meritage Homes (NYSE:<a class="ticker" href="/stock/MTH#NYSE">MTH</a>) shares were up 2.66% for the day, having made a 52-week high of $71.78.</li>
	<li>Taylor Morrison Home (NYSE:<a class="ticker" href="/stock/TMHC#NYSE">TMHC</a>) shares set a new 52-week high of $26.11 on Friday, moving up 1.48%.</li>
	<li>WD-40 (NASDAQ:<a class="ticker" href="/stock/WDFC#NASDAQ">WDFC</a>) shares were up 1.91% on Friday to hit a new 52-week high of $188.34 for a change of up 1.91%.</li>
	<li>Jack In The Box (NASDAQ:<a class="ticker" href="/stock/JACK#NASDAQ">JACK</a>) shares were down 0.63% for the day, having made a 52-week high of $93.00.</li>
	<li>Amkor Technology (NASDAQ:<a class="ticker" href="/stock/AMKR#NASDAQ">AMKR</a>) stock hit a yearly high price of $9.79. The stock was up 3.15% for the day.</li>
	<li>Frontline (NYSE:<a class="ticker" href="/stock/FRO#NYSE">FRO</a>) stock made a new 52-week high of $9.73 Friday. The stock was up 7.2% for the day.</li>
	<li>Scorpio Tankers (NYSE:<a class="ticker" href="/stock/STNG#NYSE">STNG</a>) stock on Friday broke to a yearly high of $32.74. Shares traded up 5.38%.</li>
	<li>Morguard (OTC:<a class="ticker" href="/stock/MRCBF#OTC">MRCBF</a>) stock hit a yearly high price of $151.78. The stock was up 1.87% for the day.</li>
	<li>Grupo Kuo (OTC:<a class="ticker" href="/stock/GKSDF#OTC">GKSDF</a>) shares were up 2.97% on Friday morning to hit a new 52-week high of $2.45.</li>
	<li>Universal Health Realty (NYSE:<a class="ticker" href="/stock/UHT#NYSE">UHT</a>) shares were up 0.3% on Friday to hit a new 52-week high of $104.00 for a change of up 0.3%.</li>
	<li>Killam Apartment Real Est (OTC:<a class="ticker" href="/stock/KMMPF#OTC">KMMPF</a>) shares broke to $15.49 on Friday, setting a new 52-week high with a change of up 2.08%.</li>
	<li>Independence Realty Trust (NYSE:<a class="ticker" href="/stock/IRT#NYSE">IRT</a>) stock hit a yearly high price of $14.58. The stock was up 1.57% for the day.</li>
	<li>Dream Office REIT (OTC:<a class="ticker" href="/stock/DRETF#OTC">DRETF</a>) shares hit a new 52-week high of $22.37. The stock traded up 0.51% on the session.</li>
	<li>Dream Industrial REIT (OTC:<a class="ticker" href="/stock/DREUF#OTC">DREUF</a>) shares broke to $10.04 on Friday, setting a new 52-week high with a change of up 3.41%.</li>
	<li>NexPoint Residential (NYSE:<a class="ticker" href="/stock/NXRT#NYSE">NXRT</a>) shares were up 1.35% on Friday morning to hit a new 52-week high of $48.04.</li>
	<li>Tetragon Financial Group (OTC:<a class="ticker" href="/stock/TGONF#OTC">TGONF</a>) shares set a new yearly high of $12.40 this morning. The stock was down 0.5% on the session.</li>
	<li>Sirius Real Estate (OTC:<a class="ticker" href="/stock/SRRLF#OTC">SRRLF</a>) shares hit a new 52-week high of $0.93. The stock traded up 14.81% on the session.</li>
	<li>DHT Holdings (NYSE:<a class="ticker" href="/stock/DHT#NYSE">DHT</a>) shares achieved a new 52-week high on Friday morning, hitting $6.61 with a daily change of up 4.55%.</li>
	<li>Beazer Homes USA (NYSE:<a class="ticker" href="/stock/BZH#NYSE">BZH</a>) shares set a new 52-week high of $15.05 on Friday, moving up 2.66%.</li>
	<li>Global Medical REIT (NYSE:<a class="ticker" href="/stock/GMRE#NYSE">GMRE</a>) stock on Friday broke to a yearly high of $11.82. Shares traded down 0.64%.</li>
	<li>Daily Journal (NASDAQ:<a class="ticker" href="/stock/DJCO#NASDAQ">DJCO</a>) shares were up 1.49% for the day, having made a 52-week high of $264.50.</li>
	<li>Teekay Tankers (NYSE:<a class="ticker" href="/stock/TNK#NYSE">TNK</a>) stock made a new 52-week high of $1.43 Friday. The stock was up 12.78% for the day.</li>
	<li>Zynex (NASDAQ:<a class="ticker" href="/stock/ZYXI#NASDAQ">ZYXI</a>) shares set a new 52-week high of $12.00 on Friday, moving up 6.1%.</li>
	<li>Nuveen Maryland Quality (NYSE:<a class="ticker" href="/stock/NMY#NYSE">NMY</a>) stock set a new 52-week high of $13.50 Friday morning. Over the session, the stock traded down 0.04%.</li>
	<li>Volpara Health Tech (OTC:<a class="ticker" href="/stock/VPAHF#OTC">VPAHF</a>) shares were up 0.89% on Friday morning to hit a new 52-week high of $1.13.</li>
	<li>Neuren Pharmaceuticals (OTC:<a class="ticker" href="/stock/NURPF#OTC">NURPF</a>) shares hit a yearly high of $1.44. The stock traded flat% on the session.</li>
	<li>Liberty Gold (OTC:<a class="ticker" href="/stock/LGDTF#OTC">LGDTF</a>) shares reached a new 52-week high of $0.66 on Friday morning, moving up 1.31%.</li>
	<li>Helix BioPharma (OTC:<a class="ticker" href="/stock/HBPCF#OTC">HBPCF</a>) shares broke to $0.91 on Friday, setting a new 52-week high with a change of up 30.35%.</li>
	<li>InfuSystems Holdings (AMEX:<a class="ticker" href="/stock/INFU#AMEX">INFU</a>) shares set a new yearly high of $5.52 this morning. The stock was up 4.02% on the session.</li>
	<li>Cryo-Cell International (OTC:<a class="ticker" href="/stock/CCEL#OTC">CCEL</a>) shares set a new yearly high of $8.90 this morning. The stock was up 7.36% on the session.</li>
	<li>Perma-Fix Environmental (NASDAQ:<a class="ticker" href="/stock/PESI#NASDAQ">PESI</a>) stock hit a yearly high price of $5.28. The stock was down 1.09% for the day.</li>
	<li>EnviroLeach Technologies (OTC:<a class="ticker" href="/stock/EVLLF#OTC">EVLLF</a>) shares hit a yearly high of $1.26. The stock traded up 7.5% on the session.</li>
	<li>George Risk Industries (OTC:<a class="ticker" href="/stock/RSKIA#OTC">RSKIA</a>) shares were up 3.41% on Friday morning to hit a new 52-week high of $9.10.</li>
	<li>FFD Financial (OTC:<a class="ticker" href="/stock/FFDF#OTC">FFDF</a>) stock made a new 52-week high of $58.20 Friday. The stock was up 6.9% for the day.</li>
	<li>Antisense Therapeutics (OTC:<a class="ticker" href="/stock/ATHJF#OTC">ATHJF</a>) shares were up 54.65% on Friday morning to hit a new 52-week high of $0.07.</li>
	<li>Sanara MedTech (OTC:<a class="ticker" href="/stock/SMTI#OTC">SMTI</a>) shares hit a new 52-week high of $9.50. The stock traded up 9.67% on the session.</li>
	<li>BroadVision (NASDAQ:<a class="ticker" href="/stock/BVSN#NASDAQ">BVSN</a>) shares hit a yearly high of $2.19. The stock traded up 18.84% on the session.</li>
	<li>PBS Holding (OTC:<a class="ticker" href="/stock/PBHG#OTC">PBHG</a>) stock hit a yearly high price of $0.001. The stock was up 44.93% for the day.</li>
	<li>Homeland Resources (OTC:<a class="ticker" href="/stock/HMLA#OTC">HMLA</a>) stock on Friday broke to a yearly high of $0.05. Shares traded up 36.73%.</li>
	<li>Deal A Day Group (OTC:<a class="ticker" href="/stock/DEEL#OTC">DEEL</a>) stock hit a yearly high price of $0.07. The stock was up 1.74% for the day.</li>
	<li>Echo Therapeutics (OTC:<a class="ticker" href="/stock/ECTE#OTC">ECTE</a>) shares were down 6.65% on Friday morning to hit a new 52-week high of $0.04.</li>
	<li>nFinanSe (OTC:<a class="ticker" href="/stock/NFSE#OTC">NFSE</a>) shares were down 20.0% on Friday to hit a new 52-week high of $0.01 for a change of down 20.0%.</li>
	<li>Itoco (OTC:<a class="ticker" href="/stock/ITMC#OTC">ITMC</a>) stock set a new 52-week high of $0.61 Friday morning. Over the session, the stock traded down 2.54%.</li>
	<li>AirTrona International (OTC:<a class="ticker" href="/stock/ARTR#OTC">ARTR</a>) stock made a new 52-week high of $0.0011 Friday. The stock was flat% for the day.</li>
	<li>WOD Retail Solutions (OTC:<a class="ticker" href="/stock/WODI#OTC">WODI</a>) shares broke to $1.00 on Friday, setting a new 52-week high with a change of up 300.0%.</li>
</ul>

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Helix BioPharma

News

Latest news for Helix BioPharma (OTC:HBPCF) Stock

Wednesday, June 23, 2021

Monday, December 28, 2020

Monday, April 06, 2020

Thursday, January 09, 2020

Friday, October 04, 2019